https://www.novartis.com/daily1.0 https://www.novartis.com/news/media-releases/novartis-enregistre-un-premier-trimestre-solide-malgre-la-perte-dexclusivite-de2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/loccasion-de-la-20e-journee-dentraide-communautaire-plus-de-27-5002018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-renforce-la-division-pharmaceuticals-par-la-creation-de-deux-unites2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-etend-son-partenariat-avec-medicines-malaria-venture-pour-developper-la2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-realise-un-2eme-trimestre-solide-malgre-limpact-sur-le-trimestre-du2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-convie-plusieurs-experts-au-novartis-international-biocamp-afin-de2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-realise-un-troisieme-trimestre-solide-les-produits-de-croissance1-ayant2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-access-communique-son-bilan-un-et-annonce-la-signature-dun-protocole2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-lance-sms-life-20-au-nigeria-pour-aider-ameliorer-lacces-aux2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-solide-performance-en-2016-les-produits-de-croissance1-absorbant-la2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-recu-la-certification-top-employer-suisse-20172018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ventes-en-progression-tcc1-dans-toutes-ses-divisions-les-moteurs-de2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/les-resultats-du-t2-confirment-les-previsions-de-lexercice-2017-les-tres-bons2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-et-medicines-malaria-venture-lancent-une-etude-clinique-en-afrique-pour2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-au-troisieme-trimestre-croissance-du-chiffre-daffaires-et-du-resultat2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissance2018-06-12T11:45Zyearly https://www.novartis.com/news/media-releases/novartis-enregistre-en-2017-une-belle-performance-operationnelle-et-des-innovations-majeures-entrant-ainsi-dans-une-nouvelle-phase-de-croissance-02018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-annonce-des-changements-au-sein-de-son-comite-de-direction-afin-de-soutenir-ses-priorites-strategiques2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-realise-une-bonne-performance-au-premier-trimestre-et-agi-pour-devenir-une-entreprise-plus-centree-sur-les-medicaments2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-realise-une-solide-croissance-au-deuxieme-trimestre-et-poursuit-sa-transformation-en-une-entreprise-axee-sur-les-medicaments2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-confirme-son-engagement-envers-la-suisse-en-perspective-de-la-scission-proposee-avec-novartis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-enregistre-au-troisieme-trimestre-une-forte-croissance-et-fait-preuve-dune-innovation-dynamique-incluant-des-plateformes-therapeutiques-avancees-pour2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/en-2018-novartis-enregistre-une-forte-croissance-de-ses-ventes-avec-une-expansion-de-sa-marge-core-developpe-des-plates-formes-leaders-de-traitements-de-pointe2019-01-30T06:03Zmonthly https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-02019-02-28T12:53Zmonthly https://www.novartis.com/investors/financial-data/sec-filings2018-04-12T14:50Zyearly https://www.novartis.com/careers/careers-research2018-11-26T13:37Zyearly https://www.novartis.com/our-company/awards-recognition2019-01-22T14:37Zyearly https://www.novartis.com/novartis-site-directory2018-07-20T11:41Zyearly https://www.novartis.com/our-company/corporate-responsibility/corporate-responsibility-reporting-and-disclosure/novartis-society-report/corporate-responsibility-priorities2019-01-28T17:48Zyearly https://www.novartis.com/our-company/innovative-medicines2017-11-06T09:50Zyearly https://www.novartis.com/stories/patient-perspectives/shaping-vision-healthy-aging2017-11-15T10:19Zyearly https://www.novartis.com/stories/patient-perspectives/psoriasis-story-hidden-condition2017-11-14T09:48Zyearly https://www.novartis.com/news/expanding-access-healthcare2017-06-27T15:25Znever https://www.novartis.com/news/stay-up-to-date/subscribe-requested2015-07-16T13:38Znever https://www.novartis.com/news/stay-date/thank-you-subscribing2016-05-25T11:19Znever https://www.novartis.com/news/stay-date/unsubscribe2016-02-29T15:18Znever https://www.novartis.com/news/stay-date/fill-mandatory-fields2014-12-16T20:11Znever https://www.novartis.com/our-company/corporate-responsibility/resources/corporate-responsibility-e-newsletter/thank-you-for-subscribing2017-11-03T10:01Zyearly https://www.novartis.com/our-company/corporate-responsibility/corporate-responsibility-e-newsletter/unsubscribe2017-12-01T10:52Zyearly https://www.novartis.com/stories/discovery/how-one-mans-love-sport-led-scientific-breakthrough2015-11-30T08:49Znever https://www.novartis.com/news/stay-date/subscription-cancelled2015-03-10T14:41Znever https://www.novartis.com/our-company/corporate-responsibility/resources/corporate-responsibility-e-newsletter/subscription-cancelled2017-11-03T10:00Zyearly https://www.novartis.com/investors/shareholder-information2018-04-12T13:06Zyearly https://www.novartis.com/terms-use2016-02-29T14:08Znever https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/cr-report-archive2019-03-20T13:07Zmonthly https://www.novartis.com/news/corporate-responsibility-novartis-%E2%80%93-2014-highlights2015-06-05T12:56Znever https://www.novartis.com/stories/discovery/next-generation-sequencing-may-be-key-personalized-treatments2017-11-14T08:34Zyearly https://www.novartis.com/investors/company-overview2018-04-12T10:04Zyearly https://www.novartis.com/investors/share-data-analysis2018-04-12T14:50Zyearly https://www.novartis.com/investors/company-overview/corporate-governance2019-03-21T13:49Zmonthly https://www.novartis.com/investors/financial-data/fixed-income-securities2018-09-04T13:11Zyearly https://www.novartis.com/investors/financial-data2018-06-12T11:33Zyearly https://www.novartis.com/investors/shareholder-information/novartis-registered-shares2018-04-12T14:51Zyearly https://www.novartis.com/news/trip-tradition-and-innovation-novartis-international-biocamp-2014-winners-travel-china2015-12-07T10:53Znever https://www.novartis.com/our-company/corporate-responsibility/corporate-responsibility-news2017-11-15T13:47Zyearly https://www.novartis.com/stories/discovery/could-umbilical-cords-yield-more-stem-cells-life-saving-transplants2017-11-14T07:54Zyearly https://www.novartis.com/investors/shareholder-services/american-depository-receipts-adr2018-04-12T09:58Zyearly https://www.novartis.com/investors/shareholder-information/annual-general-meeting2018-11-16T08:43Zyearly https://www.novartis.com/investors/shareholder-information/share-buy-back2018-04-12T13:02Zyearly https://www.novartis.com/investors/shareholder-information/japanese-investors-disclaimer2015-04-16T12:29Znever https://www.novartis.com/investors/financial-data/expected-currency-impact2019-03-21T10:26Zmonthly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/animals-research2018-08-09T11:46Zyearly https://www.novartis.com/investors/shareholder-information/frequently-asked-questions2019-01-30T14:36Zyearly https://www.novartis.com/news/stay-date/email-not-found2018-06-12T11:49Znever https://www.novartis.com/stories/access-healthcare/health-collaboration-russia-helped-reduce-blood-pressure-deaths2018-06-12T11:47Zyearly https://www.novartis.com/news/spelling-out-what-patients-can-expect-novartis2018-06-12T11:49Zyearly https://www.novartis.com/stories/discovery/next-phase-transplant-medicine2018-06-12T11:47Zyearly https://www.novartis.com/stories/patient-perspectives/surviving-heart-failure2018-06-12T11:46Zyearly https://www.novartis.com/investors/novartis-annual-reporting-suite/publications-order-form2019-01-28T14:10Zyearly https://www.novartis.com/stories/discovery/can-we-unlock-bodys-ability-regenerate-lost-hearing2017-09-08T14:49Zyearly https://www.novartis.com/stories/access-healthcare/making-healthcare-sustainable-developing-world2017-11-14T10:40Zyearly https://www.novartis.com/stories/access-healthcare/telemedicine-taking-health-care-worlds-far-corners2017-11-14T10:25Zyearly https://www.novartis.com/stories/access-healthcare/fighting-malaria-africa2017-11-14T10:51Zyearly https://www.novartis.com/stories/from-our-labs/young-talent-emerging-technologies-come-together-biocamp2017-11-14T08:44Zyearly https://www.novartis.com/our-company/corporate-responsibility/corporate-responsibility-e-newsletter2019-03-21T16:24Zmonthly https://www.novartis.com/stories/discovery/innovative-drug-discovery-speeds-new-treatments-patients2017-09-11T09:15Zyearly https://www.novartis.com/stories/discovery/cancer-researchers-career-inspired-childhood-loss2018-09-10T12:39Zyearly https://www.novartis.com/stories/from-our-labs/surfing-wave-big-data-analytics2018-08-10T15:23Zyearly https://www.novartis.com/stories/access-healthcare/sight-savers-jet-rescue2017-11-14T08:44Zyearly https://www.novartis.com/stories/from-our-labs/robots-speed-pace-modern-drug-discovery2018-08-10T15:12Zyearly https://www.novartis.com/stories/discovery/cancer-chronic-care-vs-search-cure2017-09-11T09:07Zyearly https://www.novartis.com/stories/patient-perspectives/protecting-our-tomorrows-portraits-meningococcal-disease2017-11-14T08:45Zyearly https://www.novartis.com/stories/discovery/combination-therapies-seeking-block-cancers-pathways-growth2017-09-07T12:03Zyearly https://www.novartis.com/stories/access-healthcare/2-million-kids-receive-malaria-medicine2017-11-14T08:42Zyearly https://www.novartis.com/stories/discovery/quest-rare-disease-treatments-drives-researchers2017-11-14T08:30Zyearly https://www.novartis.com/stories/discovery/tackling-rare-disease-working-toward-treatment-sma2015-11-30T08:45Znever https://www.novartis.com/stories/discovery/biological-battle-bulge2017-11-14T09:15Zyearly https://www.novartis.com/stories/from-our-labs/disease-pathways-key-new-drug-discovery2017-11-14T08:00Zyearly https://www.novartis.com/stories/discovery/harnessing-unique-moment-neuroscience2015-11-24T14:37Znever https://www.novartis.com/stories/discovery/personal-quest-prevent-blindness2017-11-14T08:46Zyearly https://www.novartis.com/stories/from-our-labs/3-d-printing-scientists-reinvent-research-tools2018-08-10T15:36Zyearly https://www.novartis.com/stories/discovery/fresh-look-fighting-glaucoma2019-03-22T13:45Zmonthly https://www.novartis.com/news/malaria-through-their-eyes-three-associates-kenya2018-06-12T11:49Zyearly https://www.novartis.com/stories/access-healthcare/new-drugs-could-offer-hope-malaria-patients2017-11-14T08:35Zyearly https://www.novartis.com/stories/access-healthcare/text-messages-africa-help-fight-malaria2017-11-14T08:25Zyearly https://www.novartis.com/stories/patient-perspectives/longevity-vitality-japanese-elders-provide-examples-healthy-aging2017-11-14T08:48Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/codes-policies-guidelines2018-12-12T12:45Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/positions2019-03-20T13:33Zmonthly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-oncology-access2019-01-20T14:44Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/targets-results2019-03-21T13:43Zmonthly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance2018-08-09T08:08Zyearly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/code-of-conduct2019-01-28T11:26Zyearly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/anti-bribery-anti-corruption2018-08-09T08:13Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/public-policy-advocacy2019-03-22T08:46Zmonthly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/professional-practices2018-08-09T08:15Zyearly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/data-privacy2019-01-20T15:17Zyearly https://www.novartis.com/news/improving-healthcare-africa2015-12-07T10:44Znever https://www.novartis.com/news/addressing-discomfort-through-contact-lens-innovation2015-12-07T10:33Znever https://www.novartis.com/news/copd-symptoms-strike-bright-and-early2015-12-07T10:42Znever https://www.novartis.com/news/leadership-changes-novartis-foundation-sustainable-development2015-12-07T10:45Znever https://www.novartis.com/news/novartis-biocamp-2013-perspectives-healthcare-challenges2015-12-07T10:47Znever https://www.novartis.com/news/novartis-responsible-procurement-launch-%E2%80%93-taking-our-ethical-sourcing-practices-next-level2015-12-07T10:50Znever https://www.novartis.com/news/what-significance-brain-volume-loss-atrophy-ms2015-12-07T10:54Znever https://www.novartis.com/news/biocamp-students-address-biotech-challenges2015-12-07T10:34Znever https://www.novartis.com/news/acute-heart-failure-symptoms-and-treatments2015-12-07T10:32Znever https://www.novartis.com/news/making-headway-against-malaria-africa2015-12-07T10:45Znever https://www.novartis.com/news/africa-struggles-fill-its-health-worker-shortage2015-12-07T10:34Znever https://www.novartis.com/news/interrupting-transmission-leprosy2015-12-07T10:44Znever https://www.novartis.com/news/severity-psoriasis2015-12-07T10:52Znever https://www.novartis.com/news/tackling-africa%E2%80%99s-health-challenges2015-12-07T10:52Znever https://www.novartis.com/news/novartis-recognized-among-world%E2%80%99s-most-sustainable-companies-corporate-knights-global-1002015-12-07T10:48Znever https://www.novartis.com/news/novartis-achieves-silver-class-status-robecosams-2014-sustainability-ranking2015-12-07T10:47Znever https://www.novartis.com/news/novartis-selected-finalist-pr-news%E2%80%99-csr-awards-arogya-parivar-initiative2015-12-07T10:51Znever https://www.novartis.com/news/building-research-capacity-africa2015-12-07T10:35Znever https://www.novartis.com/news/novartis-playing-leading-role-effort-eliminate-leprosy2015-12-07T10:48Znever https://www.novartis.com/news/novartis-responds-ebola-outbreak2015-12-07T10:49Znever https://www.novartis.com/news/going-final-mile-against-leprosy2015-12-07T10:43Znever https://www.novartis.com/news/meeting-patients%E2%80%99-eye-care-needs-remote-communities2015-12-07T10:46Znever https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/risk-management2018-08-09T12:28Zyearly https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/responsible-procurement2018-08-09T12:31Zyearly https://www.novartis.com/our-company/corporate-responsibility/environmental-sustainability/energy-climate2019-03-22T08:22Zmonthly https://www.novartis.com/our-company/corporate-responsibility/environmental-sustainability/water-micro-pollutants2019-03-22T15:09Zmonthly https://www.novartis.com/our-company/corporate-responsibility/environmental-sustainability/materials-waste2019-03-22T08:33Zmonthly https://www.novartis.com/our-company/corporate-responsibility/environmental-sustainability/environmental-sustainability-management2018-08-09T08:48Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/safe-workplace2019-03-04T08:15Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/living-wage2019-02-28T08:17Zyearly https://www.novartis.com/our-company/corporate-responsibility/culture-employees/community-engagement2018-08-09T09:06Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/patient-group-funding2018-08-09T11:50Zyearly https://www.novartis.com/stories/access-healthcare/talking-juergen-brokatzky-geiger-global-head-corporate-responsibility2018-06-12T11:47Zyearly https://www.novartis.com/stories/access-healthcare/treating-cataracts-leading-cause-preventable-blindness-worldwide2017-11-22T13:58Zyearly https://www.novartis.com/investors/financial-data/annual-results2019-01-22T15:17Zyearly https://www.novartis.com/investors/company-overview/novartis-fact-sheet2019-03-20T14:11Zmonthly https://www.novartis.com/stories/access-healthcare/drug-tests-brazil-could-help-broaden-access-sophisticated-treatments2017-11-15T12:23Zyearly https://www.novartis.com/stories/from-our-labs/responding-superbug-alarm2017-11-14T08:27Zyearly https://www.novartis.com/stories/patient-perspectives/experts-call-new-approach-patient-and-physician-management-type-22019-03-20T13:01Zmonthly https://www.novartis.com/stories/access-healthcare/martin-edlund-ceo-malaria-no-more-talks-about-malaria-and-power-one2017-11-14T10:34Zyearly https://www.novartis.com/stories/patient-perspectives/most-europeans-have-limited-awareness-about-heart-failure2017-11-14T09:38Zyearly https://www.novartis.com/stories/discovery/tapping-geothermal-energy-novartis-campus2018-01-29T14:14Zyearly https://www.novartis.com/stories/from-our-labs/sleuths-use-hi-tech-sensors-fight-pharmaceutical-crime2018-08-10T15:15Zyearly https://www.novartis.com/stories/patient-perspectives/glaucoma-silently-steals-sight2017-11-14T09:33Zyearly https://www.novartis.com/stories/patient-perspectives/parenting-child-rare-disease2017-11-14T09:40Zyearly https://www.novartis.com/stories/access-healthcare/talking-ann-aerts-head-novartis-foundation2017-11-15T10:00Zyearly https://www.novartis.com/stories/from-our-labs/mhealth-revolution-healthcare2018-08-10T15:27Zyearly https://www.novartis.com/stories/patient-perspectives/living-heart-failure2017-11-14T09:35Zyearly https://www.novartis.com/stories/patient-perspectives/no-longer-living-fear2017-11-15T12:23Zyearly https://www.novartis.com/stories/patient-perspectives/creative-ways-help-kids-understand-rare-diseases2017-11-14T09:26Zyearly https://www.novartis.com/stories/access-healthcare/dealing-spread-chronic-disease-africa2017-11-14T10:02Zyearly https://www.novartis.com/privacy-policy2018-11-26T14:15Zyearly https://www.novartis.com/our-company/board-directors2019-02-28T13:05Zmonthly https://www.novartis.com/stories/access-healthcare/malaria-fighter-rides-bicycle-battle-disease2018-06-12T11:47Zyearly https://www.novartis.com/news/stay-up-to-date2018-07-20T11:34Zyearly https://www.novartis.com/investors/shareholder-information/novartis-registered-shares/direct-share-purchase-plan2018-04-12T10:06Zyearly https://www.novartis.com/investors/shareholder-services/american-depository-receipts-adr/adr-voting-center2019-02-04T12:32Zyearly https://www.novartis.com/investors/shareholder-information/japanese-investors2017-05-18T15:53Znever https://www.novartis.com/investors/novartis-annual-reporting-suite/annual-report-and-20-f-archive2019-01-28T14:09Zyearly https://www.novartis.com/our-company/contact-us/media-contacts2018-06-12T11:37Zyearly https://www.novartis.com/our-company/contact-us/investor-contacts2019-02-07T14:05Zyearly https://www.novartis.com/stories/access-healthcare/confronting-global-spread-chronic-disease2017-11-14T10:01Zyearly https://www.novartis.com/stories/patient-perspectives/heart-failure-coping-one-worlds-biggest-killers2017-11-14T08:50Zyearly https://www.novartis.com/stories/access-healthcare/delivering-access-first-launch-kenya2019-03-18T15:22Zmonthly https://www.novartis.com/stories/discovery/stopping-alzheimers-disease-it-starts2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/stepping-toward-regenerative-medicine-diabetes2018-06-12T11:47Zyearly https://www.novartis.com/news/novartis-gears-meet-new-environmental-goals2015-11-12T11:22Znever https://www.novartis.com/stories/access-healthcare/bringing-modern-medicine-rural-vietnam2018-06-12T11:47Zyearly https://www.novartis.com/contact/thank-you2016-05-25T11:18Znever https://www.novartis.com/investors/share-data-analysis/share-overview2018-06-12T11:45Zyearly https://www.novartis.com/news/novartis-moves-address-superbug-threat2018-06-12T11:48Zyearly https://www.novartis.com/news/novartis-2015-financial-results2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/tackling-common-denominator-liver-disease2017-11-15T12:22Zyearly https://www.novartis.com/stories/access-healthcare/tailoring-tactics-tackle-chronic-disease-low-income-countries2017-11-14T10:28Zyearly https://www.novartis.com/investors/share-data-analysis/share-ownership2019-01-25T13:48Zyearly https://www.novartis.com/stories/patient-perspectives/dealing-psoriasis2017-11-14T09:27Zyearly https://www.novartis.com/news/media-releases/novartis-publishes-updated-2015-segment-financials-reflecting-new-division2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-analyses-show-novartis-entrestotm-reduced-cardiovascular-death-or2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-and-red-cross-partner-tackle-chronic-diseases-refugee-populations2016-12-08T16:32Znever https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-revolader-first-class-therapy-children-aged-1-year2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-ec-approval-subcutaneous-route-administration-biosimilar2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/life-dedicated-fighting-malaria2018-06-12T11:47Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-significantly-reduces-seizures-phase-iii-study-patient-02018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-celebrates-20th-annual-community-partnership-day-more-27500-associates2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-recommended-chmp-european-union-approval-treat-select-gi2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare2018-08-09T13:06Zyearly https://www.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibror-breezhalerr-superiority2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-innovative-hypertension-program-vietnam2018-12-13T08:16Zyearly https://www.novartis.com/news/fighting-high-blood-pressure-vietnam2016-05-18T12:48Znever https://www.novartis.com/news/media-releases/novartis-focuses-pharmaceuticals-division-creating-two-business-units-novartis2018-12-13T08:16Zyearly https://www.novartis.com/investors/share-data-analysis/dividend-information2019-03-07T10:31Zmonthly https://www.novartis.com/news/media-releases/monaleesa-2-trial-novartis-lee011-ribociclib-stopped-due-positive-efficacy2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure/payments-healthcare-professionals2018-11-21T12:33Zyearly https://www.novartis.com/news/media-releases/novartis-present-pivotal-data-hematologic-and-solid-tumor-cancers-2016-asco2019-01-25T07:54Zyearly https://www.novartis.com/news/media-releases/novartis-announces-investment-fortihfy-clinical-program-entrestor-and-heart2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/brain-dish-researchers-take-neurological-disorders2017-11-19T14:14Zyearly https://www.novartis.com/news/media-releases/novartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-highlights-its-strong-foundation-long-term-sustainable-growth-third2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/fighting-pneumonia-biggest-killer-young-children2017-11-14T10:52Zyearly https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-receives-eu-approval-treat-certain-types-advanced2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-show-more-50-percent-eligible-ph-cml-patients-maintain-treatment2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-pivotal-data-tafinlarr-mekinistr-demonstrated-63-percent-overall2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlarr-mekinistr-demonstrates-overall-survival2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-scientific-evidence-cosentyx-ankylosing-spondylitis-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-patients-monthly-migraine-days2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-data-demonstrates-sandoz-etanercept-and-rituximab-biosimilar-candidates2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/cancer-researchers-ready-aim-cures2017-09-07T14:39Zyearly https://www.novartis.com/news/media-releases/novartis-highlights-long-term-safety-data-revolader-adults-chronic-immune2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-data-showing-jakavir-superior-best-available-therapy-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-expands-partnership-medicines-malaria-venture-develop-next-generation2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-adds-bispecific-antibodies-its-growing-immuno-oncology-portfolio2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/largest-global-psoriasis-survey-shows-84-people-face-discrimination-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-pkc412-midostaurin-pivotal-data-published-nejm-show-60-response-rate2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-evolving-business-practices-better-educate-medical-community2016-08-09T07:36Znever https://www.novartis.com/news/media-releases/new-data-shows-sandoz-biosimilar-etanercept-candidate-has-equivalent-efficacy2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-solid-q2-despite-full-quarter-us-gleevec-generic-impact2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-launches-dailies-total1r-multifocal-contact-lenses-first-and-only-water2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-biosimilar-etanercept-recommended-fda-advisory-committee-approval-treat2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-achieves-us-approval-cypassr-micro-stent-micro-invasive-surgical-device2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/kenya-confronts-chronic-diseases-building-progress-against-aids2017-11-14T10:43Zyearly https://www.novartis.com/news/media-releases/six-leading-scientists-receive-prestigious-novartis-prizes-immunology-16th2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/students-take-challenges-digital-medicine2016-08-26T13:04Znever https://www.novartis.com/news/nurturing-next-generation-scientists2016-09-08T11:54Znever https://www.novartis.com/news/media-releases/novartis-convenes-experts-discuss-new-technologies-healthcare-novartis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/airflusalr-forspiror-showed-superiority-12-months-over-seretider-diskusr12018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ultibror-breezhalerr-consistently-more-effective-seretider-reducing2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-launches-ngenuityr-3d-visualization-system-designed-further-enhance2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/cellular-drama-heart-researchers-family2016-09-26T13:32Znever https://www.novartis.com/news/media-releases/new-novartis-point-care-nijitm-system-may-provide-earlier-diagnosis-severe2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-foundation-showcases-progress-leprosy-elimination-programs-19th2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-positive-data-ehmtic-showing-amg-334-significantly-reduces2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-novartis-data-presented-ectrims-show-benefit-gilenyar-patient-disability2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/important-new-analysis-shows-novartis-entrestor-associated-higher-relative2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/body-painter-captures-anguish-those-who-suffer-from-psoriasis2017-11-14T09:16Zyearly https://www.novartis.com/news/media-releases/novel-novartis-malaria-compound-shows-potential-be-effective-against-infections2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-positive-top-line-results-ascend-4-phase-iii-trial-zykadiar2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-three-new-fda-approvals-expanded-use-ilaris-treating-rare2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-study-shows-amg-334-significantly-reduces-monthly2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-late-breaking-data-show-cosentyx-delivers-high-and-long-lasting-skin2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-reports-over-half-psoriasis-patients-do-not-reach-achievable-treatment2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-breakthrough-therapy-lee011-plus-letrozole-demonstrates-superior2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-tafinlarr-dabrafenib-mekinistr-trametinib-demonstrate-superior-overall2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-alk-metastatic-nsclc-therapy-zykadiar-extends-progression-free-survival2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/new-orbis-flying-eye-hospital-helps-fight-blindness-china2017-11-14T10:33Zyearly https://www.novartis.com/news/media-releases/alcon-launches-cypassr-micro-stent-american-academy-ophthalmology-aao-20162018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-solid-third-quarter-growth-products1-offsetting-gleevec2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-dialogue-explore-solutions-rise-chronic-diseases-developing-world2016-11-28T18:04Znever https://www.novartis.com/news/media-releases/novartis-wins-two-prestigious-prix-galien-foundation-awards-gleevecr-recognized2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/experimental-treatment-clears-malaria-infections-small-clinical-study2017-11-14T10:04Zyearly https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-granted-fda-priority-review-first-line-treatment2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-improves-ranking-2016-access-medicine-index2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-cosentyx-data-showing-long-lasting-efficacy-psoriatic2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-newly-diagnosed2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-analysis-novartis-entrestor-data-shows-long-term-benefits-heart-failure2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-showcase-latest-innovations-development-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-amg-334-significantly-reduces-monthly-migraine-days-second2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/innovative-study-three-treatment-switches-confirms-sandoz-biosimilar-etanercept2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-commends-publication-major-report-which-recommends-broad-use-dual2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-acquires-selexys-pharmaceuticals-corporation-and-selg1-antibody2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-access-shares-one-year-learnings-and-announces-memorandum-understanding2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/working-toward2018-02-26T15:47Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/working-toward/malaria-treatment2018-02-26T12:43Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/working-toward/access-to-malaria-treatment2018-02-26T12:45Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/working-toward/capacity-building2018-02-26T12:46Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/working-toward/malaria-research-development2018-02-26T12:46Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/joining-forces2017-11-17T10:25Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/our-commitment2017-11-15T09:59Zyearly https://www.novartis.com/stories/discovery/killing-three-diseases-one-stone-lab2016-12-01T15:35Znever https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/resources2017-11-15T10:01Zyearly https://www.novartis.com/news/media-releases/novartis-seg101-crizanlizumab-formerly-selg1-significantly-reduces-frequency2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-results-first-global-registration-trial-ctl019-pediatric-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-burden-myeloproliferative-neoplasms-rare2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-interim-data-demonstrate-sandoz-proposed-biosimilar-rituximab-has-equivalent2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-shows-treatment-free-remission-rates-are-consistently-above-502018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-zykadiar-first-line-study-results-showing-166-month2018-12-13T08:16Zyearly https://www.novartis.com/news/health-experts-explore-response-chronic-illness-poor-countries2016-12-08T16:24Znever https://www.novartis.com/news/media-releases/novartis-lucentisr-received-eu-approval-new-indication-lucentis-only-treatment2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ultibror-breezhalerr-improved-lung-function-and-copd-symptoms-after2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-plus-letrozole-analyses-show-superior-pfs-across2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-launches-sms-life-20-nigeria-help-improve-access-essential-medicines2018-12-13T08:16Zyearly https://www.novartis.com/our-focus/healthcare-professionals/managed-access-programs2017-11-16T15:45Zyearly https://www.novartis.com/our-focus/navigate-novartis/healthcare-professionals/managed-access-programs/managed-access-request-form2017-11-17T14:15Zyearly https://www.novartis.com/news/eradicating-malaria-through-innovation-where-next-after-20152016-12-22T15:32Znever https://www.novartis.com/news/what-will-make-next-generation-antimalarials-game-changer-we-need-win-malaria-fight2016-12-22T15:32Znever https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative/resources/childrens-corner2017-11-15T10:08Zyearly https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-dermatology-portfolio-through-acquisition-ziarco2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-recommendation-ilarisr-treat-rare-diseases2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-votubiar-recommended-chmp-eu-approval-treat-refractory-partial2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-exclusive-option-collaboration-and-license-agreement-conatus2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-bolsters-ophthalmology-pipeline-through-acquisition-encore-vision-inc2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-invests-next-generation-therapies-reduce-cardiovascular-risk-patients2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/researcher-races-find-new-treatment-his-progressive-disease2018-06-12T11:45Zyearly https://www.novartis.com/news/novartis-2016-financial-results2018-06-12T11:40Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-solid-2016-performance-growth-products1-absorbing-gleevec-us2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-highlights-progress-towards-access-and-environmental-goals-20162018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-launches-new-trifocal-toric-intraocular-lens-patients-astigmatism2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-votubiar-receives-eu-approval-treat-refractory-partial-onset2018-12-13T08:16Zyearly https://www.novartis.com/news/medical-researchers-using-new-tools-turn-science-fiction-science-fact2017-02-08T09:21Znever https://www.novartis.com/news/media-releases/novartis-drug-zykadia-receives-fda-priority-review-first-line-use-patients-alk2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-tafinlarr-mekinistr-braf-positive-non2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-almost-all-psoriasis-patients-rapidly-regain-skin2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-data-demonstrate-sandoz-proposed-biosimilar-adalimumab-has-equivalent2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-announces-winners-inaugural-healthcare-access-challenge-sandoz-hack2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/debunking-myths-about-multiple-sclerosis2017-11-14T09:28Zyearly https://www.novartis.com/news/advancing-diabetes-awareness-and-adherence-india2017-06-19T12:24Zyearly https://www.novartis.com/stories/patient-perspectives/migraine-one-worlds-most-common-diseases2017-11-15T13:37Zyearly https://www.novartis.com/stories/patient-perspectives/patient-advocacy-work-one-mans-contributions-copd-community2017-11-14T09:44Zyearly https://www.novartis.com/stories/from-our-labs/letters-my-younger-self-female-scientists-share-their-wisdom2017-11-14T10:42Zyearly https://www.novartis.com/stories/patient-perspectives/can-better-measurement-lead-better-outcomes-look-neda4-relapsing-ms2017-11-14T09:24Zyearly https://www.novartis.com/stories/patient-perspectives/digital-health-providing-opportunities-advocacy-groups-and-community2017-11-14T09:28Zyearly https://www.novartis.com/stories/patient-perspectives/new-years-resolution-copd2017-11-14T09:38Zyearly https://www.novartis.com/news/media-releases/new-analysis-shows-novartis-entresto-improves-glycemic-control-reduced-ejection2018-12-13T08:16Zyearly https://www.novartis.com/news/5-principles-heart-our-inflammatory-joint-disease-clinical-trial-program2017-06-19T12:24Zyearly https://www.novartis.com/news/medikidz-and-copd-foundation-partnership-superhero-proportions2017-06-19T12:24Zyearly https://www.novartis.com/stories/discovery/eye-fastest-muscle-human-body2017-11-14T09:30Zyearly https://www.novartis.com/news/novartis-launches-first-apple-watch-app-visually-impaired2017-06-19T12:24Zyearly https://www.novartis.com/news/taking-action-psoriasis-patients-who-psoriasis-resolution2017-06-19T12:24Zyearly https://www.novartis.com/news/when-innovation-draws-new-future-patient-treatments2017-06-19T12:24Zyearly https://www.novartis.com/stories/discovery/striving-vanquish-leukemia2017-03-22T18:32Znever https://www.novartis.com/news/media-releases/novartis-cosentyx-first-and-only-il-17a-inhibitor-potentially-modify-course2018-12-13T08:16Zyearly https://www.novartis.com/news/beyond-pill-precision-medicine-practice2017-06-19T12:24Zyearly https://www.novartis.com/news/how-digital-technologies-are-shaping-new-normal-people-living-copd2017-06-19T12:24Zyearly https://www.novartis.com/news/industry-and-academia-collaborating-innovate-patients2017-06-19T12:24Zyearly https://www.novartis.com/news/how-we-involved-people-living-psoriasis-clinical-trial-planning2018-02-13T16:08Zyearly https://www.novartis.com/news/innovation-practice-how-we-form-partnerships-pharma2017-06-19T12:24Zyearly https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-receives-us-fda-approval-new-acrysofr-iq-restorr-25-multifocal-toric-iol2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-first-car-t-cell-therapy-bla-pediatric-and-young-adult2018-12-13T08:16Zyearly https://www.novartis.com/investors/financial-data/product-sales2019-01-28T15:02Zyearly https://www.novartis.com/our-company/executive-committee2019-02-11T15:34Zmonthly https://www.novartis.com/news/novartis-corporate-fact-sheet2019-01-30T08:46Zyearly https://www.novartis.com/news/news-archive2017-11-09T14:11Zyearly https://www.novartis.com/our-company/contact-us2018-04-03T13:18Zyearly https://www.novartis.com/news/stay-up-to-date/subscribed2015-03-09T22:21Znever https://www.novartis.com/investors/financial-data/quarterly-results2019-01-21T16:07Zyearly https://www.novartis.com/news/stay-up-to-date/not-subscribed-yet2015-03-10T16:18Znever https://www.novartis.com/news/media-releases/novartis-drug-combination-tafinlarr-mekinistr-receives-eu-approval-braf-v6002018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-strengthen-rd-pipeline-licensing-ecf843-ophthalmic-indications2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/specter-malaria-resists-treatment2017-11-14T10:29Zyearly https://www.novartis.com/news/media-releases/novartis-expands-development-programs-nash-through-clinical-collaboration2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/chemical-genetics-sleuthing-behind-modern-drug-discovery2017-11-14T07:57Zyearly https://www.novartis.com/stories/patient-perspectives/why-research-rare-diseases-matters2017-11-14T09:58Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-across-all-divisions-cc1-growth-drivers2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-3342018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-real-world-data-aan-confirms-benefit-gilenyar-four-key-measures-disease2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-approval-europe2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-announces-eu-launch-cypassr-micro-stent-micro-invasive-glaucoma-surgical2018-12-13T08:16Zyearly https://www.novartis.com/investors/share-data-analysis/share-monitor2018-04-12T14:48Zyearly https://www.novartis.com/investors/share-data-analysis/return-investment-calculator2017-11-20T14:03Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/corporate-responsibility-publications2019-03-20T13:42Zmonthly https://www.novartis.com/news/media-releases/nih-study-nejm-shows-novartis-drug-eltrombopag-first-line-therapy-standard2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/culture-employees/corporate-volunteering2018-08-09T09:09Zyearly https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rydaptr-newly-diagnosed-flt3-mutated-acute2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-exercises-exclusive-option-agreement-conatus-treatment-nash2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/two-decades-volunteering-novartis2018-04-23T13:43Zyearly https://www.novartis.com/news/media-releases/novartis-celebrates-21st-annual-community-partnership-day-over-24500-associates2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/novartis-invites-scrutiny-effort-improve-access-medicine2017-11-20T13:02Zyearly https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-initiative-tackle-hypertension-and-its2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-asco-icml-and-eha-meetings-demonstrate-meaningful-advancements2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-line-use-zykadiar-alk-positive2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-new-analyses-reinforce-potential-ultibror-breezhalerr-copd-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-expanded-use-zykadiar-first-line-alk-positive2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-focus-innovation-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/progress-reported-global-fight-against-diarrheal-disease-cryptosporidiosis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-updated-data-reinforce-efficacy-and-safety-kisqalir-ribociclib2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-landmark-study-tafinlarr-mekinistr-demonstrates-durable-survival2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-ground-breaking-collaboration-ibm-watson-health-outcomes2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-bristol-myers-squibb-evaluate2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-tasigna-receives-eu-approval-inclusion-treatment-free-remission2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-interim-results-global-pivotal-ctl019-trial-show-durable-complete2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraine2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-sustained-improvements-signs-and-symptoms-both-and-psa2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-generic-version-advair-diskusr2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-international-ag-new-patient-survey-highlights-need-more-action-help2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/helping-syrian-refugees-manage-chronic-diseases2017-11-14T10:48Zyearly https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not2018-12-13T08:16Zyearly https://www.novartis.com/news/asthma-and-exercise-why-patients-can-and-should-stay-active2017-06-22T12:39Zyearly https://www.novartis.com/news/media-releases/novartis-achieves-important-regulatory-milestone-amg-334-erenumab-migraine2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-phase-iii-study-shows-acz885-canakinumab-reduces-cardiovascular-risk2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/from-nurse-patient-facing-aggressive-blood-cancer2017-11-14T08:46Zyearly https://www.novartis.com/news/media-releases/novartis-combination-targeted-therapy-tafinlarr-mekinistr-receives-fda-approval2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-shows-half-eligible-ph-cml-cp-patients-remain-treatment-free2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-month-follow-data-show-durable-remission-rates2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-receives-positive-chmp-opinion-first-line-treatment2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/nejm-publishes-full-analysis-rydaptr-midostaurin-phase-iii-ratify-trial-newly2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-erelzir-biosimilar-etanercept-treat-multiple2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-first-line-use-zykadiar-alk-positive-advanced-non2018-12-13T08:16Zyearly https://www.novartis.com/news/alcon-survey-reveals-people-are-happier-and-more-satisfied-their-lives-after-cataract-surgery2017-07-03T15:28Zyearly https://www.novartis.com/stories/discovery/researcher-seeks-roots-plants-healing-power2018-09-10T12:32Zyearly https://www.novartis.com/news/media-releases/novartis-receives-approval-eu-cosentyx-label-update-includes-long-term2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/improving2017-11-16T12:00Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/novartis-access/how-novartis-access-works2018-02-26T15:45Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/novartis-access/tracking-our-progress2017-11-15T13:32Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/sms-life2018-02-26T12:42Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/healthy2018-03-16T13:31Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/resources2018-07-20T11:35Zyearly https://www.novartis.com/news/media-releases/q2-results-confirm-full-year-guidance-strong-pipeline-results-underpin-potential2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-confirms-5-year-data-first-and-only-fully-human-il-17a-inhibitor2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-approval-fda2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-rydaptr-midostaurin-newly-diagnosed-flt32018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-expands-partnership-world-child-cancer-help-children-access-treatment2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/systematically-exposing-vulnerabilities-cancer-cells2018-06-12T11:36Zyearly https://www.novartis.com/our-science/research-disease-areas2018-11-01T14:41Zyearly https://www.novartis.com/our-company/our-strategy2018-06-12T11:37Zyearly https://www.novartis.com/our-science/research-disease-areas/immuno-oncology2019-03-20T16:12Zmonthly https://www.novartis.com/our-science/research-disease-areas/oncology2017-12-12T09:51Zyearly https://www.novartis.com/our-science/research-disease-areas/neuroscience2019-02-05T10:02Zyearly https://www.novartis.com/our-science/research-disease-areas/cardiovascular-metabolic-diseases2018-07-03T14:22Zyearly https://www.novartis.com/our-science/research-disease-areas/autoimmunity-transplantation-inflammatory-disease2017-11-07T12:48Zyearly https://www.novartis.com/our-science/research-disease-areas/musculoskeletal-diseases2018-07-03T14:24Zyearly https://www.novartis.com/our-science/research-disease-areas/ophthalmology2017-11-07T12:50Zyearly https://www.novartis.com/our-science/research-disease-areas/respiratory-diseases2017-11-19T19:56Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/collaborations2018-10-11T12:24Zyearly https://www.novartis.com/our-science/translational-medicine2018-04-03T13:11Zyearly https://www.novartis.com/our-science/open-source-science2018-04-03T13:13Zyearly https://www.novartis.com/about-us/our-business/oncology2017-10-09T11:31Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas2017-11-06T09:54Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/acromegaly2017-11-06T09:58Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/acute-myeloid-leukemia2017-11-06T09:59Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/advanced-systemic-mastocytosis2017-11-06T09:59Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/alk-advanced-non-small-cell-lung-cancer2017-11-06T09:58Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/bone-metastasis2017-11-06T10:00Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/chronic-iron-overload2017-11-06T09:59Zyearly https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-launch-patient-trial-africa-kaf156-novel2018-12-13T08:16Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/chronic-myeloid-leukemia2017-11-06T10:04Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/cushings-disease2017-11-06T10:04Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/gastrointestinal-stromal-tumors2017-11-06T10:04Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/immune-thrombocytopenia-itp2018-05-08T13:44Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/metastatic-melanoma2017-11-06T11:09Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/multiple-myeloma2017-11-06T11:11Zyearly https://www.novartis.com/news/media-releases/novartis-appoints-bertrand-bodson-chief-digital-officer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-receives-eu-approval-first-line-treatment-hrher22018-12-13T08:16Zyearly https://www.novartis.com/our-company/contact-us/corporate-responsibility-contacts2018-09-18T13:06Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/myelofibrosis2017-11-06T11:10Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/neuroendocrine-tumors2017-11-06T11:11Zyearly https://www.novartis.com/careers/students-scholars2018-04-03T13:09Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/research-locations/novartis-institute-tropical2017-11-09T13:01Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/community-exploration-learning-lab-cell2018-07-20T11:38Zyearly https://www.novartis.com/news/media-releases/novartis-announces-analysis-published-lancet-showing-acz885-reduced-lung-cancer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz8852018-12-13T08:16Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/polycythemia-vera2017-11-06T11:12Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/renal-angiomyolipomas2017-11-06T11:12Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/renal-cell-carcinoma2017-11-06T11:15Zyearly https://www.novartis.com/stories/discovery/novartis-and-dana-farber-renew-decades-old-cancer-alliance2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/physician-scientist-donald-ganem-takes-reins-infectious-disease2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/rewriting-playbook-clinical-testing-rare-disease2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/rediscovering-power-natures-exquisite-complexity2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/cancer-cocktails-lee011-popular-combination-partner2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/cancer-cocktails-come-age2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/cancer-cocktails-ljm716-closing-common-release-valve2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/cancer-cocktails-abl001-hitting-one-target-twice2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/researcher-joins-quest-malaria-free-world2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/novartis-scientists-target-resistance-threat-malaria2018-06-12T11:47Zyearly https://www.novartis.com/stories/global-impact/neglected-tropical-diseases-take-priority2018-06-12T11:48Zyearly https://www.novartis.com/stories/access-healthcare/ghanaian-and-novartis-researchers-build-scientific-bridges2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/researchers-challenge-themselves-mini-exchanges2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/nobel-winner-shares-secret-success2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/10-big-questions-dissect-science-papers2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/why-novartis-scouts-disruptive-technology2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/vision-hacker2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/toward-precision-medicine-rare-blood-cancer2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/teamwork-drives-novartis-sma-research2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/swell-discovery-how-cells-keep-shape2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/stopping-free-radicals-their-source2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/sleep-solutions2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/sisters-plight-motivates-novartis-intern2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/rebuilding-blood2018-06-12T11:39Zyearly https://www.novartis.com/stories/discovery/rallying-troops-immune-system-fight-cancer2019-03-18T15:19Zyearly https://www.novartis.com/stories/discovery/novartis-researches-smas-genetic-roots2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/novartis-hire-applies-darwinian-mindset-drug-discovery2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/new-recruit-has-big-dreams-cancer-immunotherapy2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/mutant-protein-spreads-through-neural-circuit-huntingtons-disease2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/confidence-led-researcher-swim-against-current2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/collaborating-unravel-clues-about-neuropsychiatric-diseases2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/childhood-fight-survival-fuels-novartis-investigator2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/can-we-edit-our-genes-fight-disease2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/brink-breakthrough2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/three-lessons-ive-learned-industry-postdoc2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/what-goes-wrong-window-soul-glaucoma2019-03-22T14:48Zmonthly https://www.novartis.com/stories/from-our-labs/turning-phage2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/search-differences-make-difference2018-09-10T12:36Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-rows-cornea2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-scaffolding-neurons2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-slow-rolling-leukocyte-spells-danger2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-stains-and-scars2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-vision-health2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-kiss-me-deadly2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-muscle-fusion2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-muscles-and-mitochondria2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-neuron-factory2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-reprogramming-retina2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-riding-bronchosphere2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-ripples-rejection2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-roots-neural-development2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-fat-cells-focus2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-gut-check2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-all-nerve2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-bone-formation-brakes2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-building-barrier2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/novartis-and-pfizer-join-forces-upend-oncology-dogma2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/fixing-whats-lost-translation2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/asthma-researchers-muck-out-mucus-cells2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/5-tips-making-smart-decisions-research-projects2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/turning-heat-tumors2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/improving-science-communication-3-easy-steps2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/tuning-drugs-succeed-cells-surface2019-02-18T13:06Zyearly https://www.novartis.com/stories/discovery/stifling-danger-signals-rheumatoid-arthritis2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/researchers-uncover-missing-link-between-muscle-growth-and-power2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/researchers-aim-beat-trick-play-tumors-drug-combo2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/reaping-cancer-clues-blood2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/rare-speed-rare-disease2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/raising-deadly2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/opening-chemistry-education-world2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/nurturing-life-science-ecosystem2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/neuroscientists-restore-cell-cell-signaling-and-sociability-autism-models2018-06-12T11:46Zyearly https://www.novartis.com/stories/discovery/narrowing-species-specific-antibiotics2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/leveraging-livers-ability-heal-scarred-tissue2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/let-there-be-sight2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/intractable-tumor-cells-crippled2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/how-address-culture-gap-between-academia-and-industry-biomedicine2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/hooked-science-jay-bradner-becomes-top-researcher-novartis2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/giraffes-have-high-blood-pressure-why-dont-they-drop-dead2018-09-10T12:37Zyearly https://www.novartis.com/stories/discovery/getting-down-roots-alzheimers-disease2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/genetic-testing-alzheimers-disease-risk2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/factory-foreman-keeps-livers-line-workers-task2018-06-12T11:46Zyearly https://www.novartis.com/stories/from-our-labs/eye-disease-tracked-glitch-starburst-cells2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/eric-francotte-master-chirality2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/electrical-brainstorms-traced-genetic-mutations2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/countering-genome-reprogramming-cancer-cells2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/collaborating-unlock-secrets-microbiome2018-06-12T11:46Zyearly https://www.novartis.com/stories/discovery/clinical-trials-make-move-toward-mice2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/chan-zuckerberg-initiative-friends-novartis-scientist-mission-conquer-disease2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/crispr-genome-editing-fuels-cancer-drug-discovery2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/cancer-spies-find-drug-beating-covert-cells2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/bone-detectives-uncover-new-clues-understanding-skeletal-homeostasis2018-06-12T11:46Zyearly https://www.novartis.com/news/car-t-therapies-are-manufactured-each-individual-patient2017-10-13T14:50Zyearly https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl0192018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/turning-research-advances-innovative-medicines2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/translating-biology-medicine2018-06-12T11:47Zyearly https://www.novartis.com/stories/patient-perspectives/putting-patients-first2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/collaboration-key-unlock-new-drugs2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/scientific-renewal-keeps-discoveries-flowing2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/rare-disease-focus-patient-follow-science2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/novartis-shares-neuroscience-story-sfns-44th-annual-meeting2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/novartis-ranked-among-sciences-top-employers2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/novartis-lands-sciences-top-employer-list2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/novartis-cancer-researchers-advance-precision-medicine2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/novartis-antibody-increases-muscle-growth-mice-and-human-cell-cultures2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/mice-space2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/bedside-bench-and-back-pivotal-role-translational-medicine2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/when-tiny-brains-are-best-brain-research2018-06-12T11:46Zyearly https://www.novartis.com/stories/from-our-labs/test-tube-knees2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/science-pic-what-can-these-mushroom-structures-tell-us-about-brain-disease2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/reigniting-passion-science2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/my-transformation-from-biologist-global-citizen-scientist2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/how-i-built-mini-gut-next-no-biology-training2018-06-12T11:47Zyearly https://www.novartis.com/stories/from-our-labs/five-things-look-scientific-mentor2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/finding-new-antibiotics-fight-superbugs2018-06-12T11:48Zyearly https://www.novartis.com/stories/discovery/how-scientists-aim-expand-immunotherapy-options-cancer-patients2018-06-12T11:48Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure/transparency-disclosure2019-02-07T16:30Zyearly https://www.novartis.com/stories/from-our-labs/molecular-glue-kills-cancer-cells-mice2019-02-18T13:07Zyearly https://www.novartis.com/stories/discovery/meet-auntie-sherri-our-rheumatic-heart-disease-warrior2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/how-zika-infects-growing-brain2018-06-12T11:46Zyearly https://www.novartis.com/stories/discovery/evolution-scientist2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/compounds-spur-insulin-producing-cells-replicate-lab2018-06-12T11:48Zyearly https://www.novartis.com/stories/from-our-labs/building-brain-organoids-shed-light-disease2018-06-12T11:46Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/research-development-approach2017-11-20T14:29Zyearly https://www.novartis.com/news/media-releases/novartis-announces-ceo-joseph-jimenez-retire-novartis-2018-vasant-narasimhan2018-12-13T08:16Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/sega-tumors2017-11-06T11:16Zyearly https://www.novartis.com/our-focus/cancer/oncology-disease-areas/soft-tissue-sarcoma2017-11-06T11:16Zyearly https://www.novartis.com/news/media-releases/novartis-landmark-phase-iii-trial-shows-fingolimod-significantly-reduces2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-analysis-demonstrating-amg-334-erenumab-significantly2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-phase-iii-study-demonstrates-adjuvant-tafinlarr-mekinistr-reduced-risk2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-rituximab-accepted-review-fda2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/steven-baert-en2019-02-11T13:20Zyearly https://www.novartis.com/our-company/executive-committee/michael-ball-en2019-02-11T13:58Zyearly https://www.novartis.com/our-company/executive-committee/james-bradner-en2019-02-14T15:05Zyearly https://www.novartis.com/our-company/executive-committee/richard-francis-en2019-02-11T13:32Zyearly https://www.novartis.com/our-company/executive-committee/paul-hudson-en2019-02-11T13:34Zyearly https://www.novartis.com/our-company/executive-committee/harry-kirsch-en2019-02-11T13:38Zyearly https://www.novartis.com/our-company/executive-committee/vasant-narasimhan-en2019-02-19T09:05Zyearly https://www.novartis.com/news/media-releases/novartis-cosentyxr-sets-new-benchmark-psoriasis-robust-5-year-sustained-phase2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-terms-efficacy2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/shannon-klinger-en2019-02-11T13:41Zyearly https://www.novartis.com/our-company/executive-committee/stephen-moran-en2019-02-14T15:25Zyearly https://www.novartis.com/our-company/executive-committee/michael-willi-en2019-02-11T14:20Zyearly https://www.novartis.com/our-company/executive-committee/steven-baert-de2019-02-11T15:02Zyearly https://www.novartis.com/our-company/executive-committee/michael-ball-de2019-02-11T15:28Zyearly https://www.novartis.com/our-company/executive-committee/james-bradner-de2019-02-14T15:07Zyearly https://www.novartis.com/our-company/executive-committee/richard-francis-de2019-02-11T13:33Zyearly https://www.novartis.com/our-company/board-directors/joerg-reinhardt-en2019-02-14T15:35Zyearly https://www.novartis.com/our-company/board-directors/joerg-reinhardt-de2019-02-14T15:36Zyearly https://www.novartis.com/our-company/executive-committee/paul-hudson-de2019-02-11T13:36Zyearly https://www.novartis.com/our-company/board-directors/enrico-vanni-en2019-02-14T15:38Zyearly https://www.novartis.com/our-company/board-directors/enrico-vanni-de2019-02-14T15:39Zyearly https://www.novartis.com/our-company/board-directors/nancy-andrews-en2019-02-14T15:41Zyearly https://www.novartis.com/our-company/board-directors/nancy-andrews-de2019-02-14T15:42Zyearly https://www.novartis.com/our-company/board-directors/dimitri-azar-en2019-02-14T15:44Zyearly https://www.novartis.com/our-company/board-directors/dimitri-azar-de2019-02-14T15:45Zyearly https://www.novartis.com/our-company/board-directors/ton-buechner-en2019-02-14T15:47Zyearly https://www.novartis.com/our-company/board-directors/ton-buechner-de2019-02-14T15:47Zyearly https://www.novartis.com/our-company/board-directors/srikant-datar-en2019-02-14T15:50Zyearly https://www.novartis.com/our-company/board-directors/srikant-datar-de2019-02-14T15:51Zyearly https://www.novartis.com/our-company/executive-committee/harry-kirsch-de2019-02-11T15:08Zyearly https://www.novartis.com/our-company/board-directors/elizabeth-doherty-en2019-02-14T15:53Zyearly https://www.novartis.com/our-company/executive-committee/vasant-narasimhan-de2019-02-19T09:06Zyearly https://www.novartis.com/our-company/board-directors/elizabeth-doherty-de2019-02-14T15:54Zyearly https://www.novartis.com/our-company/board-directors/ann-fudge-en2019-03-04T15:16Zyearly https://www.novartis.com/our-company/board-directors/ann-fudge-de2019-03-04T15:19Zyearly https://www.novartis.com/our-company/board-directors/frans-van-houten-en2019-02-15T08:52Zyearly https://www.novartis.com/our-company/board-directors/frans-van-houten-de2019-02-15T08:53Zyearly https://www.novartis.com/our-company/board-directors/andreas-von-planta-en2019-02-15T08:56Zyearly https://www.novartis.com/our-company/board-directors/andreas-von-planta-de2019-02-15T08:57Zyearly https://www.novartis.com/our-company/board-directors/charles-sawyers-en2019-02-15T08:59Zyearly https://www.novartis.com/our-company/board-directors/charles-sawyers-de2019-02-15T09:00Zyearly https://www.novartis.com/our-company/board-directors/william-winters-en2019-02-28T12:56Zyearly https://www.novartis.com/our-company/board-directors/william-winters-de2019-02-28T12:57Zyearly https://www.novartis.com/our-company/board-directors/charlotte-pamer-wieser-en2019-02-15T09:05Zyearly https://www.novartis.com/our-company/board-directors/charlotte-pamer-wieser-de2019-02-15T09:06Zyearly https://www.novartis.com/our-company/executive-committee/michael-willi-de2019-02-11T15:33Zyearly https://www.novartis.com/our-company/executive-committee/stephen-moran-de2019-02-14T15:27Zyearly https://www.novartis.com/our-company/executive-committee/shannon-klinger-de2019-02-11T15:09Zyearly https://www.novartis.com/news/media-releases/novartis-xolairr-confirms-re-treatment-efficacy-chronic-spontaneous-urticaria2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/led-steven-taylor-sjogrens-syndrome-foundation-raising-awareness-little2017-11-14T08:48Zyearly https://www.novartis.com/stories/discovery/novartis-and-uc-berkeley-take-undruggable-proteins-new-collaboration2018-08-10T15:33Zyearly https://www.novartis.com/news/media-releases/novartis-drug-rydaptr-midostaurin-receives-eu-approval-newly-diagnosed-flt32018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-and-max-foundation-transform-pioneering-cancer-access-program-people2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/living-hypertension-cameroon-few-dollars-day2017-11-14T10:41Zyearly https://www.novartis.com/news/media-releases/novartis-and-uc-berkeley-collaborate-tackle-undruggable-disease-targets2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/could-digital-technology-drive-clinical-research-africa2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/eyewitness-healer-pursues-new-treatments-patients2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/innovating-trusted-class-antibiotics-attack-superbugs2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/loss-friend-liver-cancer-sharpens-focus-experimental-therapy2018-06-26T17:10Zyearly https://www.novartis.com/stories/discovery/saving-tumor-suppressors-shredder2018-06-12T11:48Zyearly https://www.novartis.com/careers/step-trainee-program2018-08-29T15:47Zyearly https://www.novartis.com/news/media-releases/alcon-introduces-new-innovations-cataract-surgery-european-society-cataract2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/minion-challenges-assumptions-about-genome2018-06-12T11:47Zyearly https://www.novartis.com/stories/access-healthcare/talking-patrice-matchaba-global-head-corporate-responsibility-novartis2017-11-15T09:57Zyearly https://www.novartis.com/news/media-releases/alcon-receives-ce-mark-first-its-kind-autonometm-preloaded-intraocular-lens-iol2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/going-global-meet-local-needs-china2017-10-10T14:01Zyearly https://www.novartis.com/stories/patient-perspectives/choosing-right-care2018-06-12T11:45Zyearly https://www.novartis.com/stories/patient-perspectives/future-chronic-myeloid-leukemia-evolving2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/talking-bruno-strigini-why-were-entering-transformative-time-cancer-care2018-06-12T11:47Zyearly https://www.novartis.com/stories/patient-perspectives/learning-mutation-drives-my-disease2018-06-12T11:45Zyearly https://www.novartis.com/stories/patient-perspectives/lung-cancer-test-or-not-test2018-06-12T11:45Zyearly https://www.novartis.com/stories/patient-perspectives/meet-tj-sharpe2018-06-12T11:47Zyearly https://www.novartis.com/stories/patient-perspectives/giving-small-community-big-voice2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/women-science-annie-martin2018-06-12T11:34Zyearly https://www.novartis.com/stories/discovery/women-science-renee-rodgers2018-08-10T15:03Zyearly https://www.novartis.com/stories/discovery/women-science-virginia-lazala2018-06-12T11:34Zyearly https://www.novartis.com/stories/discovery/women-science-tania-small2018-06-12T11:34Zyearly https://www.novartis.com/stories/discovery/women-science-lilli-petruzzelli2018-06-12T11:34Zyearly https://www.novartis.com/stories/discovery/women-science-hannah-mosca2018-06-12T11:34Zyearly https://www.novartis.com/stories/patient-perspectives/rare-every-day-experiences-challenges-and-victories-rare-disease2018-06-12T11:47Zyearly https://www.novartis.com/stories/discovery/taking-clinical-trials-next-level-through-technology2018-06-12T11:34Zyearly https://www.novartis.com/stories/patient-perspectives/inside-cancer-diagnosis2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/women-science-medy-attalla2018-06-12T11:34Zyearly https://www.novartis.com/stories/patient-perspectives/your-genes-your-melanoma2018-06-12T11:45Zyearly https://www.novartis.com/stories/discovery/researchers-phd-leads-medical-breakthrough-rare-skin-disease2018-09-10T12:33Zyearly https://www.novartis.com/news/novartis-host-stakeholder-dialogue-ways-improve-access-healthcare-lower-income-countries2018-06-12T11:45Zyearly https://www.novartis.com/stories/access-healthcare/fighting-respiratory-disease-source2017-11-14T10:51Zyearly https://www.novartis.com/stories/patient-perspectives/coping-eye-disease-and-fading-vision-late-life2017-11-14T08:51Zyearly https://www.novartis.com/stories/from-our-labs/bringing-virtual-reality-lab2018-08-10T15:32Zyearly https://www.novartis.com/stories/discovery/eye-patients-mind-innovation2018-06-12T11:45Zyearly https://www.novartis.com/stories/patient-perspectives/groundskeeper-tackles-cancer-several-ways2017-11-14T10:49Zyearly https://www.novartis.com/stories/patient-perspectives/fitness-trainer-strives-keep-his-mothers-mind-limber2018-01-08T09:24Zyearly https://www.novartis.com/news/media-releases/novartis-drug-revolader-shows-long-term-disease-control-chronicpersistent-immune2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/patrice-matchaba-en2019-02-14T15:23Zyearly https://www.novartis.com/our-company/executive-committee/patrice-matchaba-de2019-02-14T15:24Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-growth-top-and-bottom-line-all-divisions-q32018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-combination-adjuvant-therapy-tafinlarr-mekinistr-receives-fda2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/exploring-longstanding-questions-about-heart-disease2017-11-01T08:04Zyearly https://www.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-proposed-biosimilar-pegfilgrastim-accepted-ema-regulatory-review2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-paradigms-data-show-children-and-adolescents-ms-had-82-lower-relapse2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-present-first-its-kind-evidence-cosentyxr-potential-maintain-mobility2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/targeting-roots-sjogrens-syndrome2017-11-15T12:34Zyearly https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr2018-12-13T08:16Zyearly https://www.novartis.com/our-science/novartis-global-pipeline2019-03-20T13:46Zmonthly https://www.novartis.com/our-company2018-11-28T10:44Zyearly https://www.novartis.com/our-focus/neuroscience2017-11-17T10:30Zyearly https://www.novartis.com/our-focus/patients-caregivers2018-09-12T10:25Zyearly https://www.novartis.com/our-focus/ophthalmology2017-11-15T17:24Zyearly https://www.novartis.com/our-focus/healthcare-professionals2017-11-14T18:43Zyearly https://www.novartis.com/our-company/corporate-responsibility2019-01-28T16:45Zyearly https://www.novartis.com/our-focus2017-11-15T10:39Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research2019-02-19T10:28Zyearly https://www.novartis.com/investors2019-03-14T14:02Zmonthly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business2017-11-21T18:10Zyearly https://www.novartis.com/our-focus/cardio-metabolic2017-11-15T16:44Zyearly https://www.novartis.com/our-science2017-11-14T18:39Zyearly https://www.novartis.com/careers2019-02-27T13:27Zmonthly https://www.novartis.com/our-company/diversity-inclusion2019-03-13T11:06Zmonthly https://www.novartis.com/our-company/novartis-oncology2019-02-21T11:36Zmonthly https://www.novartis.com/our-focus/respiratory2018-11-12T09:02Zyearly https://www.novartis.com/news/media-releases/novartis-presents-data-ash-patients-serious-blood-disorders-lymphoma-leukemia2018-12-13T08:16Zyearly https://www.novartis.com/news2019-01-29T11:22Zyearly https://www.novartis.com/our-focus/immunology-dermatology2017-11-20T13:47Zyearly https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-expanded-collaboration-banner-alzheimers-institute2018-12-13T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes2018-12-12T22:47Zyearly https://www.novartis.com/our-science/postdoc-program/novartis-discovery-postdoctoral-fellowship2019-03-07T13:02Zmonthly https://www.novartis.com/our-science/postdoc-program/publications2017-11-16T14:57Zyearly https://www.novartis.com/our-science/postdoc-program/leadership2018-12-12T22:50Zyearly https://www.novartis.com/our-science/postdoc-program/recognition2017-11-22T12:07Zyearly https://www.novartis.com/our-focus/cancer2019-02-28T08:38Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology2019-03-20T19:20Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry2019-01-04T22:37Zyearly https://www.novartis.com/our-science/postdoc-program2019-03-06T17:13Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/alyson-freeman-phd2017-11-15T07:32Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/carl-uli-bialucha-phd2017-11-18T11:48Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/catherine-sabatos-peyton-phd2017-11-15T07:58Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/claudio-thoma-phd2018-12-11T15:53Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/e-robert-mcdonald-iii-phd2017-11-15T08:02Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/giorgio-g-galli-phd2019-01-08T00:22Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/haihui-lu-phd2017-11-15T08:08Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/huaixiang-hao-phd2017-11-15T08:06Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/katie-campbell-phd2017-11-19T21:23Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/marta-cortes-cros-phd2017-11-15T08:12Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/matthew-j-meyer-phd2017-11-15T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/rebecca-leary-phd2017-11-15T08:22Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/tony-dalessio2017-11-22T14:51Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/zainab-jagani-phd2017-11-18T12:07Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/alexei-karpov-phd2017-11-15T08:05Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/andreas-lingel-phd2017-11-21T13:09Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/andreas-marzinzik-phd2017-11-17T09:35Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/eric-martin-phd2017-11-17T15:17Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/folkert-reck-phd2018-10-08T18:49Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/frederic-berst-phd2017-11-27T16:15Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/jeff-mckenna-dphil2017-11-16T15:18Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/kian-tan-phd2017-11-16T15:20Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/marie-helene-larraufie-phd2017-11-15T08:38Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/patrick-chene-phd2017-11-15T08:40Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/patrick-j-rudewicz-phd2017-11-17T09:36Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/piro-siuti-phd2017-11-15T08:41Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/razvan-nutiu-phd2017-11-15T08:43Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/richard-robinson-phd2017-11-15T08:44Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/robert-grotzfeld-phd2017-11-17T09:37Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/steve-canham-phd2017-11-21T13:10Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/tejas-pathak-phd2017-11-15T08:46Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/valery-polyakov-phd2017-11-15T08:48Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences2019-02-22T04:07Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology2019-01-18T15:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/antoine-de-weck-phd2018-01-11T16:00Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/audrey-kauffmann-phd2017-11-15T08:49Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/hanneke-jansen-phd2017-11-16T15:22Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/robert-pearlstein-phd2017-11-15T08:52Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/trixie-wagner-phd2017-11-18T12:23Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/viktor-hornak-phd2017-11-21T11:59Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/catherine-regnier-phd2017-11-18T12:27Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/daniela-cipolletta-phd2017-11-15T08:58Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/elisabetta-traggiai-phd2017-11-15T08:59Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/frederic-bornancin-phd2017-11-18T12:33Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/juan-zhang-phd2018-10-04T17:03Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/max-warncke-phd2017-11-21T10:18Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/miriam-bibel-phd2017-11-15T09:05Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/martin-alexander-schneider-phd2017-11-18T12:30Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/thomas-calzascia-phd2017-11-18T12:26Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/tobias-junt-phd2017-11-16T14:11Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal2019-01-04T23:00Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/viviana-cremasco-phd2017-11-15T09:13Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology2019-03-05T16:35Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology2019-01-18T15:27Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine2018-05-08T16:45Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology2018-11-05T14:06Zyearly https://www.novartis.com/our-company/novartis-pharmaceuticals2018-04-04T08:35Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/charles-wartchow-phd2018-12-12T22:37Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/david-glass-md2017-11-15T09:28Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/estelle-trifilieff-phd2017-11-15T09:29Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/mara-fornaro-phd2017-11-18T12:06Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/mark-nash-dphil2017-11-18T12:04Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/olivier-leupin-phd2017-11-18T12:02Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/bilada-bilican-phd2017-11-15T09:40Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/computational-sciences/florian-nigsch-phd2018-01-09T10:58Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/ivan-galimberti-phd2017-11-18T11:58Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/rajeev-sivasankaran-phd2017-11-15T09:45Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/ricardo-dolmetsch-phd2018-08-24T08:47Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/taeho-kim-phd2017-11-15T09:47Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/ann-marie-faust-phd2017-11-18T11:48Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/beat-nyfeler-phd2017-11-15T09:51Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/david-rowlands-phd2018-01-11T15:58Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/dennis-rice-phd2017-11-15T09:53Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/dominic-hoepfner-phd2017-11-15T09:55Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/feng-cong-phd2017-11-15T09:56Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/frederic-bassilana-phd2017-11-18T11:45Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/jeremy-jenkins-phd2017-11-18T11:43Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/john-koschwanez-phd2017-11-15T10:02Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/philipp-hoppe-phd2017-11-15T10:11Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/stephen-helliwell-phd2018-01-05T13:23Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/yan-feng-phd2017-11-15T10:14Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/yi-yang-phd2017-11-18T11:38Zyearly https://www.novartis.com/our-company/our-culture-and-values2018-10-09T12:11Zyearly https://www.novartis.com/news/media-releases/novartis-reports-positive-results-phase-iii-trial-kisqalir-ribociclib2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-study-data-demonstrating-cosentyxr-reduced-signs-and-symptoms2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-seeks-leadership-cosentyxr-showing-no-radiographic-progression2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission2018-12-13T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/aron-jaffe-phd2018-09-04T15:29Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/felix-lohmann-phd2017-11-15T10:19Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/giorgia-jurisic-phd2017-11-18T11:37Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/heinz-ruffner-phd2017-11-15T10:28Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/jan-tchorz-phd2017-11-21T13:21Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/susan-kirkland-phd2017-11-18T11:32Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/regenerative-medicine/tewis-bouwmeester-phd2017-11-18T11:20Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/jean-michel-rondeau-phd2017-11-18T11:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/nicolas-thoma-phd2017-11-18T11:13Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/wilhelm-weihofen-phd2018-08-27T16:00Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/veli-pekka-jaakola-phd2017-11-18T11:04Zyearly https://www.novartis.com/our-science/postdoc-program/andreas-bender-phd2017-11-15T08:12Zyearly https://www.novartis.com/our-science/postdoc-program/sereina-riniker-phd2017-11-15T08:12Zyearly https://www.novartis.com/our-science/postdoc-program/boxun-lu-phd2017-11-15T08:13Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/karin-briner-phd2017-11-09T13:40Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/jeff-porter-phd2017-11-22T14:26Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/jeffrey-engelman-md-phd2017-11-10T14:52Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/sandra-jacob-phd2017-11-10T14:54Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/darrin-stuart-phd2017-11-10T14:57Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/natasha-aziz-phd2017-11-10T14:58Zyearly https://www.novartis.com/novartis-home2019-03-21T13:41Zweekly1.0 https://www.novartis.com/our-science/postdoc-program/leadership/don-ganem-md2017-11-10T14:47Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/ricardo-dolmetsch-phd2017-11-10T14:50Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/tewis-bouwmeester-phd2017-11-16T15:07Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/feng-cong-phd2017-11-10T14:55Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/aron-b-jaffe-phd2017-11-10T14:56Zyearly https://www.novartis.com/our-science/postdoc-program/leadership/johanna-hanneke-jansen-phd2017-11-10T14:59Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/novartis-access2018-02-26T12:24Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/malaria-initiative2018-07-20T11:35Zyearly https://www.novartis.com/our-company/contact-us/office-locations2018-04-03T13:17Zyearly https://www.novartis.com/news/media-releases/novartis-highlights-its-differentiated-late-stage-pipeline-rd-update-and2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-novartis-entrestor-real-world-evidence-data-shows-beneficial-impact-quality2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/punjab-province-pakistan-signs-agreement-novartis-access-against-chronic2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/conversations-patient-advocates-ron-hollander-president-inca2017-11-24T12:09Zyearly https://www.novartis.com/stories/discovery/small-viruses-could-accelerate-cell-and-gene-therapy-research2018-08-10T15:30Zyearly https://www.novartis.com/stories/discovery/women-science-shilpa-shah-mehta2018-05-30T13:29Zyearly https://www.novartis.com/our-focus/healthcare-professionals/investigator-initiated-trials2019-03-18T15:33Zmonthly https://www.novartis.com/investors/novartis-annual-reporting-suite2019-01-30T16:19Zyearly https://www.novartis.com/news/media-releases/novartis-ascp-and-acs-join-forces-fight-cancer-ethiopia-uganda-and-tanzania2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-data-sabcs-across-broad-range-breast-cancer-patient-populations-combination-treatments-and-lines-therapy2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-data-reinforces-clinical-basis-switching-sandoz-biosimilar-medicines2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-tasignar-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ultibror-breezhalerr-significantly-improved-copd-patients-lung-function-after-direct-switch-from-seretider2018-12-13T08:16Zyearly https://www.novartis.com/news/biosimilar-drugs-have-potential-save-more-usd-54-billion2017-12-04T12:50Zyearly https://www.novartis.com/news/media-releases/novartis-announces-phase-iii-strive-data-published-nejm-demonstrating-significant-and-sustained-efficacy-erenumab-migraine-prevention2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-cosentyxr-first-biologic-show-long-term-efficacy-nail-and-palmoplantar-psoriasis-which-can-impact-90-psoriasis-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/exploring-future-access-healthcare-lower-income-countries2017-11-30T15:17Zyearly https://www.novartis.com/stories/discovery/researchers-overcome-hurdles-test-experimental-malaria-drug2017-12-05T10:25Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/finton-sirockin-phd2017-12-08T19:56Zyearly https://www.novartis.com/stories/patient-perspectives/one-boys-quest-battle-cancer2017-12-08T13:27Zyearly https://www.novartis.com/stories/access-healthcare/pioneering-business-approach-expands-healthcare-indian-villages2017-12-08T10:32Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-first-and-only-cdk46-inhibitor-show-superior-median-pfs-compared-oral-endocrine-therapy-first-line-treatment-prospective-randomized-phase-iii2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-tender-offer-advanced-accelerator-applications-commences2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim-matches-reference-medicine2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-crizanlizumab-shown-prolong-time-patients-first-sickle-cell-pain-crisis-subgroup-analysis-sustain-study2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-oncology-head-retire2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/open-science-demystified2018-08-10T15:26Zyearly https://www.novartis.com/stories/discovery/organic-dealmaker-drug-discovery2018-03-20T16:47Zyearly https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlarr-mekinistr-granted-fda-priority-review-adjuvant-treatment-stage-iii-braf-v600-mutation-positive-melanoma2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-tasignar-approved-fda-first-and-only-cml-therapy-treatment-free-remission-data-its-label2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-drug-promactar-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-advances-head-head-superiority-trials-cosentyxr-versus-humirar-and-proposed-biosimilar-adalimumab2018-12-13T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/eusebio-manchado-phd2018-01-24T15:49Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/ellie-growcott-phd2018-11-05T13:41Zyearly https://www.novartis.com/news/media-releases/novartis-appoints-elizabeth-barrett-oncology-head2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/environmental-sustainability2019-03-22T15:20Zmonthly https://www.novartis.com/news/novartis-recognized-global-leader-sustainable-water-and-climate-management2018-01-29T16:58Zyearly https://www.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-new-data-reinforces-superiority-cosentyxr-versus-stelarar-achieving-skin-clearance-psoriasis-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-granted-us-fda-priority-review-kymriahtm-tisagenlecleucel-formerly-ctl019-adults-rr-dlbcl2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-2017-financial-results2018-06-12T11:40Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-good-operational-performance-and-landmark-innovation-2017-entering-our-next-growth-phase2019-01-25T07:54Zyearly https://www.novartis.com/news/media-releases/novartis-reports-erenumab-met-all-primary-and-secondary-endpoints-unique-phase-iiib-study-episodic-migraine-patients-who-have-failed-multiple-prior-preventive2019-01-25T07:55Zyearly https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-advanced-accelerator-applications-sa-and-announces-commencement-subsequent-offering-period2019-01-25T07:54Zyearly https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars2019-01-25T07:55Zyearly https://www.novartis.com/news/media-releases/novartis-exclusively-licenses-first-ophthalmology-gene-therapy-all-markets-outside-us-milestone-patients-rare-inherited-vision-loss2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/advanced-accelerator-applications-receives-fda-approval-lutatherar-treatment-gastroenteropancreatic-neuroendocrine-tumors2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/tracking-patients-progress-radio-signals-and-machine-learning2018-08-10T15:11Zyearly https://www.novartis.com/stories/discovery/compound-designed-fight-alzheimers-disease-shows-promise-lab2018-02-08T13:47Zyearly https://www.novartis.com/our-company/executive-committee/katja-roth-pellanda-phd-en2019-02-14T15:28Zyearly https://www.novartis.com/our-company/executive-committee/bertrand-bodson-en2019-02-11T13:22Zyearly https://www.novartis.com/stories/access-healthcare/partnering-improved-cancer-care-around-globe2018-02-02T16:26Zyearly https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-updated-analysis-from-eliana-trial-showing-longer-term-durable-remissions-kymriahtm-children-young-adults-rr-all2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/bertrand-bodson-de2019-02-11T15:04Zyearly https://www.novartis.com/our-company/executive-committee/katja-roth-pellanda-phd-de2019-02-14T15:29Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/xiaomo-jiang-phd2018-09-12T14:35Zyearly https://www.novartis.com/news/media-releases/novartis-completes-subsequent-offering-period-tender-offer-advanced-accelerator-applications-sa2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/living-breast-cancer-uganda2018-02-02T16:29Zyearly https://www.novartis.com/our-focus/patients-caregivers/novartis-commitment-patients-and-caregivers2019-02-13T16:56Zyearly https://www.novartis.com/stories/discovery/potential-weight-loss-treatment-takes-shape-help-from-patients2019-02-05T14:42Zyearly https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-cosentyxr-label-update-include-moderate-severe-scalp-psoriasis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/women-science-cathryn-clary2018-08-10T15:24Zyearly https://www.novartis.com/stories/access-healthcare/women-science-fionnuala-doyle2018-08-10T15:20Zyearly https://www.novartis.com/news/media-releases/novartis-forms-alliance-develop-medicines-treating-infectious-diarrheal-disease2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/taking-obesity2019-02-05T14:50Zyearly https://www.novartis.com/news/media-releases/novartis-new-cosentyxr-data-confirms-robust-efficacy-and-quality-life-improvements-scalp-psoriasis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-new-data-show-cosentyxr-improved-quality-life-over-5-years-two-thirds-patients-moderate-severe-plaque-psoriasis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/treatment-novartis-ultibror-breezhalerr-improved-cardiac-function-copd-patients-lung-hyperinflation2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-and-pear-therapeutics-develop-digital-therapeutics-patients-schizophrenia-and-multiple-sclerosis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/positive-gains-are-needed-accelerate-change-women-lung-disease2018-04-19T12:44Zyearly https://www.novartis.com/news/media-releases/novartis-xolairr-recommended-new-global-chronic-urticaria-guideline2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-expands-alliance-science-37-advance-virtual-clinical-trials-program2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee-support-strategic-priorities2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/building-boot-camps-immune-cells-near-tumors2018-08-10T15:30Zyearly https://www.novartis.com/news/novartis-foundation-joins-global-partnership-zero-leprosy2018-03-19T09:20Zyearly https://www.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapies2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/malaria-still-disrupting-lives-despite-progress2018-03-23T09:43Zyearly https://www.novartis.com/news/media-releases/novartis-drug-tasignar-approved-fda-treat-children-rare-form-leukemia2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/dna-encoded-molecules-provide-new-edge-cancer-drug-hunts2018-06-12T11:34Zyearly https://www.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-ms2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-infliximab2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-priorities2018-12-13T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/jay-larrow-phd2018-04-06T09:47Zyearly https://www.novartis.com/news/media-releases/novartis-present-predictability-data-brolucizumab-namd-from-pivotal-hawk-and-harrier-trials-arvo2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/counting-combos-complex-liver-diseases2018-04-11T15:43Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/martin-renatus-phd2018-04-06T10:31Zyearly https://www.novartis.com/our-company/executive-committee/steffen-lang-en2019-02-14T15:09Zyearly https://www.novartis.com/our-company/executive-committee/steffen-lang-de2019-02-14T15:10Zyearly https://www.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entrestor-improves-physical-and-social-activity-hfref-patients-versus-enalapril2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/meet-martin-grobusch-malaria-fighter2018-04-10T08:32Zyearly https://www.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovation2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leader2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/african-experts-call-renewed-global-drive-beat-malaria2018-04-23T08:00Zyearly https://www.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetes2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-financial-results-q1-20182018-06-12T11:34Zyearly https://www.novartis.com/news/media-releases/novartis-appoints-john-tsai-head-global-drug-development-and-chief-medical-officer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-strong-first-quarter-and-acted-become-more-focused-medicines-company2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription-digital-therapeutics-patients-substance-use-disorder-and-opioid-use-disorders2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-first-its-kind-evidence-aan-reinforcing-robust-and-consistent-efficacy-aimovigtm-erenumab-migraine-patients-multiple-treatment-failures2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarials2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-tender-offer-avexis-commences2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-novartis-analyses-aan-show-siponimods-efficacy-disability-and-cognition-secondary-progressive-ms-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/celebrating-community-partnership-day2018-04-24T10:22Zyearly https://www.novartis.com/investors/financial-data/quarterly-results/2018-q1-transcript2018-07-20T11:31Zyearly https://www.novartis.com/news/media-releases/novartis-launches-focalview-app-providing-opportunity-patients-participate-ophthalmology-clinical-trials-from-home2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/tj-sharpe-why-clinical-trials-matter2018-05-03T14:51Zyearly https://www.novartis.com/our-company/executive-committee/john-tsai-en2019-02-14T15:19Zyearly https://www.novartis.com/our-company/executive-committee/john-tsai-de2019-02-14T15:20Zyearly https://www.novartis.com/stories/discovery/machine-learning-poised-accelerate-drug-discovery2018-08-10T15:10Zyearly https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-tafinlarr-mekinistr-adjuvant-treatment-braf-v600-mutant-melanoma2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-provides-update-proposed-acquisition-avexis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-complete-response-letter-from-us-fda-proposed-biosimilar-rituximab2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-cares-project-100-commits-reducing-cataract-blindness-globally2018-12-13T08:16Zyearly https://www.novartis.com/news/essential-consultants-updates2019-03-20T13:26Zweekly https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-gilenyar-first-disease-modifying-therapy-pediatric-relapsing-multiple-sclerosis2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/women-science-mimi-huizinga2018-08-10T15:21Zyearly https://www.novartis.com/stories/discovery/quest-new-measure-mental-health2018-08-13T19:25Zyearly https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-avexis-inc2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-arrow-trial-assess-mechanistic-superiority-direct-il-17a-inhibition-cosentyxr-over-il-23-inhibition-tremfyar2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avexis-inc2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committee2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-strategy-focus-company-and-drive-sustainable-growth2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancer2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/immuno-oncology-researchers-seek-build-smart-drug-combos2018-05-29T12:56Zyearly https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-prevention2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zesslyr-infliximab-gastroenterological-rheumatological-and-dermatological-diseases2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entrestor2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/fda-expedites-review-novartis-drug-promactar-first-line-severe-aplastic-anemia-saa2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/robert-weltevreden-en2019-02-11T13:55Zyearly https://www.novartis.com/our-company/executive-committee/robert-weltevreden-de2019-02-11T13:56Zyearly https://www.novartis.com/our-company/executive-committee/natacha-theytaz-en2019-02-11T14:16Zyearly https://www.novartis.com/our-company/executive-committee/natacha-theytaz-de2019-02-11T15:32Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-adalimumab2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovigr-erenumab-prevention-migraine2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-completes-sale-stake-consumer-healthcare-joint-venture-gsk-usd130-billion2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/open-resources-novartis-help-drive-innovation2018-09-10T12:29Zyearly https://www.novartis.com/news/media-releases/new-novartis-data-presented-asco-find-nearly-half-cml-patients-treated-tasignar-remain-remission-almost-three-years-after-stopping-therapy2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/third-novartis-phase-iii-trial-shows-kisqalir-combination-therapy-significantly-improves-pfs-hrher2-advanced-breast-cancer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-jco-publication-lutatherar-netter-1-data-showing-significantly-longer-time-deterioration-key-quality-life-measures-patients-progressive2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-data-advance-understanding-role-il-17a-and-reinforce-cosentyxr-leadership-spondyloarthritis2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/women-science-kristen-harrington-smith2018-06-20T08:56Zyearly https://www.novartis.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zesslyr-infliximab-and-erelzir-etanercept-rheumatoid-arthritis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-life2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-study-real-world-data-concludes-jakavi-associated-reduction-risk-death-and-dangerous-blood-clots-patients-rare-blood-cancer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbcl2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysofr-iq-panoptixr-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgery2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skin2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovigr-erenumab-patients-chronic-and-episodic-migraine2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bn2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/drug-development-gets-big-data-analytics-boost2018-09-27T08:03Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-kymriahr-treating-two-aggressive-blood-cancers-marking-important-medical-advance-patients-europe2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-financial-results-q2-20182018-07-24T15:38Zyearly https://www.novartis.com/news/media-releases/novartis-delivers-solid-growth-second-quarter-and-continues-transformation-focused-medicines-company2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kisqalir-now-first-and-only-cdk46-inhibitor-indicated-us-first-line-therapy-specifically-premenopausal-women-and-initial-therapy-fulvestrant2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-demonstrates-commitment-lead-immuno-dermatology-licensing-il-17c-compound-atopic-dermatitis2018-12-13T08:16Zyearly https://www.novartis.com/investors/financial-data/quarterly-results/2018-q2-transcript2019-01-16T16:35Zyearly https://www.novartis.com/news/media-releases/novartis-renews-drug-donation-egatenr-triclabendazole-until-2022-reaffirming-its-commitment-fight-against-liver-fluke2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/discovery-gives-cystic-fibrosis-researchers-new-direction2018-08-01T17:10Zyearly https://www.novartis.com/stories/access-healthcare/meet-manuel-cobos-transplant-surgeon-and-researcher2018-09-10T12:30Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles2019-01-30T06:56Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/donations2019-01-20T15:13Zyearly https://www.novartis.com/our-company/corporate-responsibility/culture-employees2018-08-09T09:02Zyearly https://www.novartis.com/our-company/corporate-responsibility/reporting-disclosure2019-01-29T08:20Zyearly https://www.novartis.com/news/media-releases/novartis-combination-tafinlarr-mekinistr-receives-positive-chmp-opinion-adjuvant-treatment-braf-v600-mutation-positive-melanoma2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-biosimilar-hyrimozr-adalimumab2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-marks-new-era-migraine-patients-eu-approval-aimovigr-first-its-kind-treatment-specifically-designed-migraine-prevention2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/embracing-big-data-understand-complex-diseases2018-08-24T13:36Zyearly https://www.novartis.com/stories/discovery/new-drug-manufacturing-tools-change-pharma-chemistry2018-08-13T15:09Zyearly https://www.novartis.com/our-company/corporate-responsibility/corporate-responsibility-reporting-and-disclosure/novartis-society-report2019-03-21T13:38Zweekly https://www.novartis.com/news/media-releases/novartis-appoints-dr-klaus-moosmayer-chief-ethics-risk-and-compliance-officer2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/neuroscientists-target-alzheimer-silent-stage2018-08-27T08:57Zyearly https://www.novartis.com/stories/discovery/researchers-boost-understanding-t-cell-therapy-blood-cancer2018-10-01T15:02Zyearly https://www.novartis.com/stories/discovery/teaming-academia-discover-medicines2018-08-27T13:49Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/company-overview-en2019-01-29T10:37Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-at-a-glance-en2019-01-29T10:04Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/major-developments-en2019-01-28T13:52Zyearly https://www.novartis.com/news/media-releases/solar-1-trial-novartis-investigational-alpha-specific-pi3k-inhibitor-byl719-alpelisib-meets-primary-endpoint-hrher2-advanced-breast-cancer-pik3ca-mutation2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/innovative-medicines-en2019-01-28T13:37Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/sandoz-en2019-01-28T16:19Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/alcon-en2019-01-28T17:19Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/research-en2019-01-28T14:44Zyearly https://www.novartis.com/news/media-releases/novartis-announces-new-data-show-entresto-sacubitrilvalsartan-can-be-initiated-early-safely-hospitalized-patients-after-acute-heart-failure-episode2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/company-overview-de2019-01-29T12:57Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/major-developments-de2019-01-29T09:54Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/pharmaceuticals-at-a-glance-en2019-01-28T14:10Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/global-drug-development-en2019-01-28T14:50Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-oncology-at-a-glance-en2019-01-29T10:36Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/associates-en2019-01-28T17:13Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/corporate-responsibility-en2019-01-28T16:59Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/sandoz-at-a-glance-en2019-01-29T10:07Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-oncology-at-a-glance-de2019-01-29T10:39Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/alcon-at-a-glance-en2019-01-29T10:09Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-technical-operations-en2019-01-28T14:55Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/management-en2019-01-28T15:24Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-at-a-glance-de2019-01-29T10:02Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/pharmaceuticals-at-a-glance-de2019-01-28T21:33Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/sandoz-at-a-glance-de2019-01-29T10:13Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/alcon-at-a-glance-de2019-01-29T10:11Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/sandoz-de2019-01-29T13:08Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/alcon-de2019-01-29T13:05Zyearly https://www.novartis.com/news/media-releases/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical-glaucoma2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/european-commission-approves-novartis-combination-therapy-tafinlar-mekinist-adjuvant-treatment-braf-v600-mutation-positive-melanoma2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/research-de2019-01-29T07:37Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/global-drug-development-de2019-01-29T07:45Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/novartis-technical-operations-de2019-02-06T12:49Zyearly https://www.novartis.com/stories/patient-perspectives/abcdes-melanoma-prevention-and-detection2018-08-30T13:47Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/associates-de2019-01-29T13:03Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/management-de2019-01-29T13:00Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/corporate-responsibility-de2019-01-29T09:13Zyearly https://www.novartis.com/our-science/novartis-clinical-trials2018-11-29T14:07Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/how-are-clinical-trials-done2018-11-29T14:07Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/what-should-i-know-joining-clinical-trial2018-11-29T14:07Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/what-questions-should-i-ask-i-participate-clinical-trial2018-11-29T14:07Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/what-questions-do-participants-usually-have2018-11-29T14:07Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/glossary-clinical-trial-terms2018-11-29T14:07Zyearly https://www.novartis.com/stories/access-healthcare/nudging-bias-out-organization2018-09-06T13:49Zyearly https://www.novartis.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo2018-12-13T08:16Zyearly https://www.novartis.com/our-science/novartis-clinical-trials/what-clinical-trial2018-11-29T14:07Zyearly https://www.novartis.com/our-company/executive-committee/david-endicott-en2019-02-11T14:01Zyearly https://www.novartis.com/our-company/executive-committee/david-endicott-de2019-02-11T14:02Zyearly https://www.novartis.com/news/media-releases/alcon-confirms-commitment-switzerland-ahead-proposed-spinoff-from-novartis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-survey-shows-psoriasis-patients-want-treatment-effect-beyond-clear-skin2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-landmark-paradigms-study-demonstrating-significant-benefit-gilenya-children-and-adolescents-ms2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-real-world-evidence-confirms-efficacy-and-safety-benefits-cosentyx-daily-life-psoriasis-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/launch-alcon-experience-academy-reinforces-commitment-training-and-education-eye-care-professionals2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/worlds-largest-alzheimers-survey-reveals-most-adults-believe-cure-will-be-developed-their-lifetime2018-12-13T08:16Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/nikolaus-stiefl-phd2018-09-25T14:48Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-positive-chmp-opinion-proposed-biosimilar-pegfilgrastim2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-gilenya-treatment-children-and-adolescents-ms-marking-major-medical-advance-young-ms-patients-europe2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-positive-chmp-opinion-one-time-gene-therapy-luxturna-treat-children-and-adults-rare-inherited-retinal-disease2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-file-new-lucentis-ranibizumab-indication-retinopathy-prematurity-rop-rare-disease-premature-infants-often-leads-blindness2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/new-analysis-novartis-phase-iii-brolucizumab-rth258-data-reinforces-superior-reduction-retinal-fluid-key-marker-disease-activity-namd2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-five-grant-recipients-excellence-ophthalmology-vision-award-xova-nonprofit-sustainable-eye-health-initiatives2018-12-13T08:16Zyearly https://www.novartis.com/privacy-policy/novartis-binding-corporate-rules-bcr2018-11-07T12:24Zyearly https://www.novartis.com/stories/discovery/digital-health-ecosystem-gets-boost-novartis-biome2018-11-20T10:29Zyearly https://www.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals2018-12-13T08:16Zyearly https://www.novartis.com/our-science/novartis-biome2018-11-27T10:29Zyearly https://www.novartis.com/stories/discovery/being-and-becoming-data-science-company2018-11-14T15:08Zyearly https://www.novartis.com/news/media-releases/sandoz-healthcare-access-challenge-hack-returns-seeking-digital-solutions-local-healthcare-access-challenges2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/women-science-marjorie-eiref2018-10-10T13:56Zyearly https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-siponimod-first-and-only-drug-shown-meaningfully-delay-disability-progression-typical-spms-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crises-vs-placebo-during-sustain-study2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/breadth-data-ectrims-underpins-novartis-relentless-commitment-decoding-science-multiple-sclerosis-ms-and-decreasing-patient-burden2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-new-data-from-first-direct-head-head-trial-demonstrate-superior-efficacy-gilenya-over-copaxone-patients-relapsing-remitting-multiple2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-announces-global-resolution-biosimilar-adalimumab-patent-disputes-securing-patient-access2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-financial-results-q3-20182018-10-18T09:57Zyearly https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-delivered-strong-growth-and-innovation-during-third-quarter-including-progressing-advanced-therapy-platforms-drive-future-growth2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-5-year-data-psoriatic-arthritis-and-ankylosing-spondylitis-reinforces-cosentyx-leadership-spondyloarthritis2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/women-science-alexandra-bach-weidmuller2018-11-05T16:00Zyearly https://www.novartis.com/stories/from-our-labs/women-science-cyndy-grosskreutz2018-11-05T15:58Zyearly https://www.novartis.com/news/media-releases/novartis-announces-presentation-new-lutathera-netter-1-data-esmo-demonstrating-significant-improvement-pfs-regardless-baseline-liver-tumor-burden2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-phase-ii-geometry-mono-1-trial-investigational-medicine-capmatinib-inc280-shows-positive-results-patients-met-mutated-advanced-nsclc2018-12-13T08:16Zyearly https://www.novartis.com/stories/from-our-labs/women-science-jennifer-allport-anderson2018-11-05T16:14Zyearly https://www.novartis.com/stories/from-our-labs/women-science-jean-silveri2018-11-05T16:36Zyearly https://www.novartis.com/stories/from-our-labs/women-science-wendy-winckler2018-11-05T16:10Zyearly https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-nearly-doubles-median-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-compared-fulvestrant2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-combi-ad-study-tafinlar-mekinist-continues-demonstrate-relapse-free-survival-benefit-patients-braf-v600-mutant-stage-iii-melanoma2018-12-13T08:16Zyearly https://www.novartis.com/investors/financial-data/quarterly-results/2018-q3-transcript2018-10-24T08:54Zyearly https://www.novartis.com/news/media-releases/novartis-announces-lancet-publication-pioneering-study-migraine-prevention-showing-efficacy-aimovig-where-other-treatments-have-failed2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-develop-smart-suite-digital-health-platform-cataract-surgery2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/realities-living-premenopausal-metastatic-breast-cancer2018-11-01T16:08Zyearly https://www.novartis.com/news/media-releases/novartis-receives-approval-cosentyx-label-update-europe-include-dosing-flexibility-psoriatic-arthritis2018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/flexibility-novartis-ana-graf2018-10-29T13:24Zyearly https://www.novartis.com/stories/access-healthcare/flexibility-novartis-robert-gschwentner-and-stefan-lackner2018-10-29T13:24Zyearly https://www.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-clinical-collaboration-pfizer-advance-treatment-nash2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/importance-caregivers2018-11-02T18:32Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/wolfgang-jahnke-phd2018-11-05T14:50Zyearly https://www.novartis.com/stories/discovery/artificial-intelligence-decodes-cancer-pathology-images2018-11-12T11:08Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoztm-adalimumab-adaz2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-data-ash-and-sabcs-show-strength-pipeline-and-portfolio-hematology-and-oncology2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-decides-not-pursue-us-biosimilar-rituximab-will-focus-robust-biosimilar-portfolio-unmet-access-and-sustainability-needs2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-rd-update-highlights-industry-leading-development-pipeline-including-potential-blockbusters-and-advanced-therapy-platforms2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles/research-development2019-01-20T14:20Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles/affordability2019-01-20T14:23Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles/strengthening-healthcare-systems2019-01-20T14:27Zyearly https://www.novartis.com/news/media-releases/new-novartis-study-supports-entresto-foundational-hfref-therapy-and-hospital-initiation-appropriate-stabilized-heart-failure-patients2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/alcon-files-initial-form-20-f-registration-statement-sec-proposed-spinoff-plans-investor-days-new-york-and-london2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/breaking-through-barriers2018-11-19T09:45Zyearly https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-expand-kisqali-combination-therapy-all-women-hrher2-locally-advanced-or-metastatic-breast-cancer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/fda-approves-novartis-drug-promacta-first-line-saa-and-grants-breakthrough-therapy-designation-additional-new-indication2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorder2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-rises-second-place-2018-access-medicine-index2018-12-13T08:16Zyearly https://www.novartis.com/our-company/novartis-partnering2018-12-05T10:12Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/nigel-sheail2018-12-05T09:54Zyearly https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-disease2019-01-25T07:53Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/prakash-raman2018-12-05T09:55Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/neil-johnston2018-12-05T09:55Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/syed-kazmi2018-12-05T09:56Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/ulrich-uili-osswald2018-12-05T09:57Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/ben-toogood2018-12-05T09:58Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/keren-haruvi2018-12-05T09:58Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/jean-marc-sequier2018-12-05T09:59Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/jeremy-sohn2018-12-05T10:03Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team/nancy-griffin2018-12-05T10:05Zyearly https://www.novartis.com/our-company/novartis-partnering/partnering-leadership-team2018-12-05T10:08Zyearly https://www.novartis.com/our-company/novartis-partnering/key-therapeutic-areas-focus2018-12-05T10:06Zyearly https://www.novartis.com/stories/from-our-labs/reimagining-protein-sequencing2018-11-30T15:42Zyearly https://www.novartis.com/stories/discovery/close-look-cryo-electron-microscopy2018-11-30T15:43Zyearly https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-london2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo-pegfilgrastim2018-12-13T08:16Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/access-principles/novartis-2018-access-stakeholder-event2019-01-20T14:13Zyearly https://www.novartis.com/news/discussing-innovative-solutions-address-unmet-healthcare-needs-asia2019-01-30T06:57Zyearly https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-gilenya-children-and-adolescents-ms-making-it-first-and-only-oral-disease-modifying-treatment-these-patients-europe2018-12-13T08:16Zyearly https://www.novartis.com/our-company/executive-committee/klaus-moosmayer-en2019-02-14T15:12Zmonthly https://www.novartis.com/our-company/executive-committee/klaus-moosmayer-de2019-02-14T15:13Zmonthly https://www.novartis.com/our-company/novartis-united-states2019-03-01T08:44Zmonthly https://www.novartis.com/stories/discovery/from-patient-patient-advocate-how-cancer-diagnosis-fueled-new-career-path2018-12-05T17:02Zyearly https://www.novartis.com/news/media-releases/novartis-announces-new-crizanlizumab-seg101-data-analysis-sickle-cell-disease-and-investment-sentry-clinical-program2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-longer-term-analyses-from-pivotal-kymriah-trials-showed-durable-responses-are-maintained-patients-advanced-blood-cancers2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/real-world-data-show-novartis-drug-revolade-improves-outcomes-itp-patients-compared-other-second-line-therapies2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-avxs-101-one-time-treatment-designed-address-genetic-root-cause-sma-type-12018-12-13T08:16Zyearly https://www.novartis.com/stories/access-healthcare/improving-lives-through-community-based-care2019-01-28T17:33Zyearly https://www.novartis.com/stories/access-healthcare/flexibility-novartis-deepti-mittal2019-01-07T12:12Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/stakeholder-dialogues2018-12-04T15:11Zyearly https://www.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data2018-12-13T08:16Zyearly https://www.novartis.com/stories/patient-perspectives/changing-landscape-cancer-treatment2018-12-10T09:50Zyearly https://www.novartis.com/stories/access-healthcare/flexibility-novartis-peter-canavan2019-01-07T12:13Zyearly https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/women-science-susanne-schaffert2018-12-12T09:41Zyearly https://www.novartis.com/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral2018-12-13T08:16Zyearly https://www.novartis.com/stories/discovery/bringing-real-change-people2019-03-05T14:29Zmonthly https://www.novartis.com/news/media-releases/sandoz-inc-and-pear-therapeutics-obtain-fda-clearance-reset-otm-treat-opioid-use-disorder2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-self-administration-xolair-across-all-indications2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars-anticipating-growing-demand-diabetes-burden-rises2018-12-19T06:18Zyearly https://www.novartis.com/news/media-releases/alcon-announces-acquisition-tear-film-innovations-inc2018-12-19T06:18Zyearly https://www.novartis.com/news/media-releases/novartis-announces-new-ceo-oncology-business-unit2018-12-20T06:03Zyearly https://www.novartis.com/news/media-releases/novartis-announces-offer-acquire-cellforcure-expand-manufacturing-capacity-innovative-cell-and-gene-therapies2018-12-20T16:03Zyearly https://www.novartis.com/news/media-releases/novartis-receives-european-commission-ec-approval-expanded-indication-kisqali-ribociclib2018-12-21T06:18Zyearly https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-endocyte2018-12-21T14:03Zyearly https://www.novartis.com/our-company/executive-committee/susanne-schaffert-en2019-02-14T15:15Zmonthly https://www.novartis.com/our-company/executive-committee/susanne-schaffert-de2019-02-14T15:15Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/cara-brocklehurst-phd2019-01-08T00:06Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/chemistry/peter-meier-phd2019-01-08T00:01Zyearly https://www.novartis.com/our-science/clinical-trials2018-04-03T13:12Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/musculoskeletal/sophie-brachat-phd2019-01-08T00:23Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/tobias-schmelzle-phd2019-01-08T00:21Zyearly https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-us-launch-reset-otm-help-treat-opioid-use-disorder2019-01-07T22:03Zyearly https://www.novartis.com/news/media-releases/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-prevention-vaso-occlusive-crises-sickle-cell-disease2019-01-08T06:18Zyearly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/patents-licensing2019-01-28T17:49Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/qian-huang-phd2019-01-18T15:21Zyearly https://www.novartis.com/our-company/novartis-united-states/us-country-leadership-team2019-03-01T08:48Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/pathways-biology/robert-esterberg-phd2019-01-18T15:22Zyearly https://www.novartis.com/our-science/postdoc-program/research-themes/immunology/james-rush-phd2019-01-18T15:11Zyearly https://www.novartis.com/news/novartis-2018-financial-results2019-03-19T16:22Zweekly https://www.novartis.com/news/media-releases/novartis-delivered-strong-sales-growth-core-margin-expansion-built-leading-advanced-therapy-platforms-and-focused-company-20182019-01-30T06:03Zmonthly https://www.novartis.com/investors/financial-data/quarterly-results/2018-q4-and-full-year-results-transcript2019-02-28T16:38Zmonthly https://www.novartis.com/guidelines/novartis-instagram-community-guidelines2019-02-06T15:02Zmonthly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/delivering-promise-cell-and-gene-therapy-patients2019-02-19T10:27Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/structural-biology/bing-wang-phd2019-02-13T02:39Zmonthly https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-egaten-treatment-fascioliasis-neglected-tropical-disease2019-02-28T09:02Zmonthly https://www.novartis.com/our-company/corporate-responsibility/expanding-access-healthcare/novartis-social-business/novartis-social-business-report-20182019-02-20T09:24Zmonthly https://www.novartis.com/stories/discovery/enabling-130000-employees-grow-organization-committed-continuous-learning2019-03-19T16:21Zweekly https://www.novartis.com/stories/from-our-labs/how-19th-century-technology-speeding-drug-discovery2019-02-27T16:47Zmonthly https://www.novartis.com/our-science/postdoc-program/research-themes/neurobiology/robert-altshuler-phd2019-03-05T15:48Zmonthly https://www.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina2019-02-25T06:18Zmonthly https://www.novartis.com/our-focus/cancer/supporting-people-affected-systemic-mastocytosis/no-disease-too-small-patient-guide2019-03-13T08:21Zweekly https://www.novartis.com/our-company/board-directors/patrice-bula-de2019-03-25T09:45Zweekly https://www.novartis.com/our-focus/cancer/supporting-people-affected-systemic-mastocytosis/no-disease-too-small-fact-sheet2019-03-19T16:39Zweekly https://www.novartis.com/our-focus/cancer/supporting-people-affected-systemic-mastocytosis/questions-ask-your-doctor-about-systemic-mastocytosis2019-03-04T08:50Zmonthly https://www.novartis.com/our-focus/cancer/supporting-people-affected-systemic-mastocytosis2019-02-28T08:38Zmonthly https://www.novartis.com/news/media-releases/novartis-issues-summary-financial-information-alcon-eye-care-business-ahead-shareholder-vote-proposed-spin2019-02-25T23:03Zmonthly https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-02019-02-28T12:53Zmonthly https://www.novartis.com/stories/access-healthcare/novartis-access-impact-evaluation-progress-update-our-work-boston-university2019-03-01T15:53Zmonthly https://www.novartis.com/news/media-releases/novartis-data-confirm-rapid-response-and-high-efficacy-cosentyx-psoriasis-patients-first-time-china2019-03-04T06:18Zmonthly https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-superior-improvements-psoriasis-patients-quality-life-versus-janssens-il-23-stelara2019-03-05T06:18Zmonthly https://www.novartis.com/our-science/postdoc-program/novartis-innovation-postdoctoral-fellowship2019-03-06T17:03Zmonthly https://www.novartis.com/news/media-releases/three-winners-2019-sandoz-healthcare-access-challenge-hack-are-announced-sxsw2019-03-10T23:48Zmonthly https://www.novartis.com/stories/discovery/visualizing-immuno-oncology-research2019-03-19T14:01Zweekly https://www.novartis.com/news/global-equal-parental-leave-policy-all-novartis-parents2019-03-14T14:47Zweekly https://www.novartis.com/news/media-releases/novartis-announces-change-sandoz-leadership2019-03-14T06:18Zweekly https://www.novartis.com/news/media-releases/novartis-joins-global-chagas-disease-coalition-and-also-announces-first-multinational-prospective-randomized-study-people-chronic-chagas-cardiomyopathy2019-03-14T16:33Zweekly https://www.novartis.com/news/media-releases/alcon-announces-acquisition-powervision-inc2019-03-18T06:18Zweekly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/mariela-jaskelioff-phd2019-03-20T19:12Zweekly https://www.novartis.com/our-science/postdoc-program/research-themes/cancer-biology/javad-golji-phd2019-03-20T19:13Zweekly https://www.novartis.com/stories/discovery/experimental-gene-therapy-discovered-house-enters-clinical-testing2019-03-21T13:18Zweekly https://www.novartis.com/news/media-releases/novartis-plans-alcon-spin-april-9-20192019-03-22T06:03Zweekly https://www.novartis.com/news/contributing-breath-fresh-air-zambian-health-care2015-12-07T10:41Znever https://www.novartis.com/our-science/clinical-trials/clinical-trial-information-disclosure2017-11-15T15:25Zyearly https://www.novartis.com/news/report-says-new-family-drugs-could-save-billions2015-12-07T10:51Znever https://www.novartis.com/investors/event-calendar2019-01-31T10:27Zyearly https://www.novartis.com/our-science/novartis-institutes-biomedical-research/research-locations2017-11-20T18:50Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-trotz-verlust-der-exklusivrechte-gleevec2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/am-20-tag-der-partnerschaft-engagieren-sich-weltweit-uber-27-500-novartis2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-fokussiert-ihre-division-pharmaceuticals-durch-schaffung-der2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erweitert-partnerschaft-mit-medicines-malaria-venture-zur-entwicklung2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-im-2-quartal-solide-ergebnisse-trotz-us-generikakonkurrenz-fur2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/experten-diskutieren-am-novartis-international-biocamp-neue-technologien-im2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-solide-ergebnisse-wobei-die2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-access-informiert-uber-erfahrungen-im-ersten-jahr-und-gibt-memorandum2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-fuhrt-sms-life-20-nigeria-ein-um-den-zugang-zu-unentbehrlichen2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-2016-solide-ergebnisse-wobei-die-wachstumsprodukte1-den-verlust2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/sandoz-pharmaceuticals-ag-als-top-arbeitgeber-schweiz-2017-ausgezeichnet2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-umsatzsteigerungen-allen-divisionen-kwk1-wobei-wachstumstreiber2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/die-ergebnisse-im-zweiten-quartal-bestatigen-die-jahresprognosen-starke2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-und-medicines-malaria-venture-starten-afrika-eine-patientenstudie-mit2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-steigert-im-dritten-quartal-umsatz-und-gewinn-allen-divisionen2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-gibt-rucktritt-des-onkologie-chefs-bekannt2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ernennt-elizabeth-barrett-zur-chefin-onkologie2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphase2018-06-12T11:45Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphase-02018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-aktionare-genehmigen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung-zur-unterstutzung-strategischer-prioritaten2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-verkauft-beteiligung-consumer-healthcare-joint-venture-fur-usd-13-milliarden-gsk-um-sich-auf-strategische-prioritaten-zu-konzentrieren2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-verzeichnet-ein-starkes-erstes-quartal-und-ergreift-schritte-um-ein-starker-fokussiertes-arzneimittelunternehmen-zu-werden2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitung2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-schullabor-empfangt-hunderttausendsten-besucher2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschafts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erhalt-positive-chmp-stellungnahme-fur-kymriahr-zur-behandlung-zweier-aggressiver-blutkrebsarten-ein-wichtiger-medizinischer-fortschritt-fur2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-im-zweiten-quartal-ein-solides-wachstum-und-setzt-die-transformation-zu-einem-fokussierten-arzneimittelunternehmen-fort2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-ernennt-dr-klaus-moosmayer-zum-chief-ethics-risk-and-compliance-officer2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erhaelt-die-zulassung-fuer-seine-car-t-zell-therapie-kymriah-tisagenlecleucel-von-der-europaeischen-kommission2018-12-13T08:16Zyearly https://www.novartis.com/news/novartis-corporate-fact-sheet/innovative-medicines-de2019-01-29T13:17Zyearly https://www.novartis.com/news/media-releases/alcon-bestaetigt-vor-dem-vorgeschlagenen-spin-von-novartis-das-engagement-der-schweiz2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-im-dritten-quartal-starkes-wachstum-und-treibt-innovationen-wie-fortschrittlichetherapieplattformen-voran-um-das-zukuenftige-wachstum-zu2018-12-13T08:16Zyearly https://www.novartis.com/news/media-releases/novartis-erzielt-2018-ein-kraeftiges-umsatzwachstum-bei-gleichzeitiger-steigerung-der-kerngewinnmarge-baut-wegweisende-therapie%21plattformen-auf-und-fokussiert2019-01-30T06:03Zmonthly https://www.novartis.com/news/media-releases/die-aktionaere-von-novartis-heissen-der-generalversammlung-alle-antraege-des-verwaltungsrates-gut2019-02-28T12:53Zmonthly https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-significantly-reduces-seizures-phase-iii-study-patients2018-06-12T11:49Zyearly